| Period End | Type | Status | Affected | % Workforce | Announced | Expected Completion | Geography | Segment / Function | Charge | Source | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 41 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charges for the six months ended June 27, 2026 (Q2 portion: $29 million); primarily severance and employee-related costs. No employee counts disclosed; total 2026-2027 charge estimate not yet determined. Restructuring liability balance was $43 million at June 27, 2026. | ||
| 2026-06-27 | divestiture_reduction | completed | 2026-01-01 | 2026-03-28 | Not disclosed | Global Specialty Products | USD 2 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Loss on disposal of businesses recorded in the quarter ended March 28, 2026; amount is included within the $41 million six-month restructuring charge (not additive). No headcount impact disclosed; announcement date not specified, quarter of occurrence used. | ||
| 2026-06-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 29 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan to integrate acquisitions and right-size operations. Q2 2026 charges of $29M include $27M severance and $2M other costs. No employee count disclosed. | ||
| 2026-06-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 41 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | YTD 2026 charges of $41M include $34M severance, $2M impairment, $3M exit costs, and $2M loss on disposal. No employee count disclosed. | ||
| 2026-06-27 | restructuring | in_progress | USD 29,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2026-06-27 | restructuring | in_progress | Eliminations And Reconciling Items | USD 29,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Plan2024 | USD 41,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 27,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 13,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Corporate Non Segment / Loss On Disposal Of Business / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-06-27 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charges of $12M in Q1 2026 (severance $7M, exit costs $2M, impairment $1M, loss on business disposal $2M); no employee counts disclosed; includes $2M loss on disposal of businesses in Global Specialty Products | ||
| 2026-03-28 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | All Segments | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan to integrate acquisitions and right-size operations. Q1 2026 charges of $12M primarily for severance, facility exits, and a $2M loss on disposal of businesses in Global Specialty Products. Employee count affected not disclosed. | ||
| 2026-03-28 | restructuring | in_progress | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2026-03-28 | restructuring | in_progress | Eliminations And Reconciling Items | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Plan2024 | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Corporate Non Segment / Loss On Disposal Of Business / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-03-28 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global Distribution and Value-Added Services | USD 43 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2025 charges under the 2024 Plan (integrate acquisitions, right-size operations, increase efficiencies): $40M severance and employee-related costs, $(3)M impairment/accelerated depreciation and amortization of right-of-use and other long-lived assets, $5M exit and other costs, and $1M loss on disposal of a business. No employee counts disclosed. Program-level: accrued restructuring liability of $48M at fiscal year-end (total $49M including completed 2022 Plan), primarily severance; charges for 2026-2027 not yet estimated. | |||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global Specialty Products | USD 44 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2025 charges under the 2024 Plan: $22M severance and employee-related costs, $6M impairment/accelerated depreciation and amortization, $4M exit and other costs, and $12M loss on disposal of a business. No employee counts disclosed. | |||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global Technology | USD -2 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2025 net credit under the 2024 Plan: $4M severance and employee-related costs and $(1)M impairment, more than offset by a $(5)M net gain on disposal of a business. No employee counts disclosed. | |||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Corporate | USD 20 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2025 charge under the 2024 Plan consists entirely of severance and employee-related costs. No employee counts disclosed. Segment-level charges across the four components sum to the $105M FY2025 total restructuring and related costs. | |||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | All segments (integration of acquisitions, right-sizing operations) | USD 105 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2025 activity only: $105M total charges, of which $86M was severance and employee-related costs; primarily severance, accelerated ROU/fixed asset amortization and exit costs. No employees-affected count disclosed. Program runs through end of 2027; 2026-2027 charge estimates not yet determined. | ||
| 2025-12-27 | divestiture_reduction | completed | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology | USD 13 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2025 disposals under the 2024 Plan: $1M loss (GDVAS), $12M loss (Global Specialty Products), and a net gain (Global Technology); included in the $105M restructuring charge. No headcount removed disclosed. | ||||
| 2025-12-27 | acquisition_addition | completed | Global (includes Canada and Brazil transactions completed in Q4 FY2025) | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology | USD 392 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Aggregate FY2025 acquisition consideration of $392M; ownership interests 60%-100%. No headcount added disclosed. Acquisitions represent ~0.10% of total net sales and were excluded from the ICFR assessment. | ||||
| 2025-12-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology | USD 105 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 2024 Plan committed August 6, 2024. Charges of $105 million recorded in FY2025 primarily for severance, accelerated amortization, and exit costs. Employee count not explicitly disclosed in the provided text. | ||
| 2025-12-27 | restructuring | in_progress | Eliminations And Reconciling Items | USD 105,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Plan2024 | USD 105,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Plan2024 / Global Specialty Products | USD 12,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 40,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 22,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 20,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 86,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD -3,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 6,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD -1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 9,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Specialty Products | USD 12,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Technology | USD -5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Corporate Non Segment / Facility Closing / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Facility Closing / Plan2024 | USD 8,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 43,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 44,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD -2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 20,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | Plan2022 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-12-27 | restructuring | in_progress | USD 105,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2025-09-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 82 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan to integrate acquisitions, right-size operations and increase efficiencies; $34M charged in Q3 2025 and $82M in nine months 2025; $155M cumulative since inception; no employee affected count disclosed; severance accrual balance $53M at 2025-09-27 | ||
| 2025-09-27 | other | completed | 2022-08-01 | 2024-07-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2022 Plan completed 2024-07-31; no charges recorded in current quarter or YTD 2025; residual liability of $2M remains at 2025-09-27; no employee affected count disclosed | |||
| 2025-09-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 34 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan to integrate acquisitions and right-size operations. Q3 2025 charges of $34M primarily for severance and employee-related costs. | ||
| 2025-09-27 | restructuring | in_progress | 2024-08-06 | 2027-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 82 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan YTD 2025 charges of $82M primarily for severance and employee-related costs. | ||
| 2025-09-27 | restructuring | in_progress | USD 34,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-09-27 | restructuring | in_progress | Eliminations And Reconciling Items | USD -34,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Plan2024 | USD 34,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 13,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 27,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 14,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 11,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Corporate Non Segment / Loss On Disposal Of Business / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-09-27 | restructuring | in_progress | Plan2022 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global Distribution and Value-Added Services | USD 26 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charge for six months ended 2025-06-28 (Q2 charge $14M); primarily severance, accelerated ROU/fixed asset amortization and exit costs. No employee counts disclosed. | |||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global Specialty Products | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charge for six months ended 2025-06-28 (Q2 charge $7M). No employee counts disclosed. | |||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global Technology | USD 2 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charge for six months ended 2025-06-28 (no Q2 charge). No employee counts disclosed. | |||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Corporate | USD 8 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan charge for six months ended 2025-06-28 (Q2 charge $2M). Program-wide: $48M YTD charges, $46M severance accrual at 2025-06-28; filer expects charges through end of 2025 with amount not yet determined. No employee counts disclosed. | |||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 23 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan charges for Q2 2025 were $23 million, primarily for severance and employee-related costs. Employee count not disclosed. | ||
| 2025-06-28 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 48 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan charges for YTD 2025 were $48 million, primarily for severance and employee-related costs. Employee count not disclosed. | ||
| 2025-06-28 | restructuring | in_progress | USD 23,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-06-28 | restructuring | in_progress | Intersegment Elimination | USD -23,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Plan2024 | USD 23,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 11,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 18,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Loss On Disposal Of Business / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Corporate Non Segment / Loss On Disposal Of Business / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Loss On Disposal Of Business / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 14,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-06-28 | restructuring | in_progress | Plan2022 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 25 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan to integrate recent acquisitions, right-size operations and increase efficiencies; Q1 2025 charge of $25M primarily severance and employee-related costs; charges expected through end of 2025, amount not yet estimated; no employee counts disclosed | ||
| 2025-03-29 | acquisition_addition | completed | Not disclosed | Global Distribution and Value-Added Services | USD 61 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Multiple 100%-owned acquisitions during Q1 2025 totaling $61M consideration; headcount added not disclosed | ||||
| 2025-03-29 | restructuring | in_progress | 2024-08-06 | 2025-12-31 | Global | Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, Corporate | USD 25 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan charges primarily related to severance and employee-related costs. Employee count not disclosed. | ||
| 2025-03-29 | restructuring | in_progress | USD 25,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-03-29 | restructuring | in_progress | Intersegment Elimination | USD -25,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Plan2024 | USD 25,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 10,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 22,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Impairment And Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Corporate Non Segment / Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-03-29 | restructuring | in_progress | Plan2022 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | 2024-08-06 | Company-wide; charges recorded in Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, and Corporate | USD 73 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | 2024 Plan to integrate recent acquisitions, right-size operations and increase efficiencies. FY2024 charges by segment: GD&VAS $38M; Global Specialty Products $23M; Global Technology $10M; Corporate $2M. Components: severance and employee-related costs $44M; accelerated amortization of lease and long-lived assets $12M; loss on disposal of a portion of a business $15M (includes $13M goodwill/intangibles impairment, Global Specialty Products); exit costs $2M. Headcount affected not disclosed. Additional charges expected in 2025; amount not yet estimated. | ||||
| 2024-12-28 | restructuring | completed | 2022-08-01 | 2024-07-31 | Company-wide; FY2024 charges recorded in Global Distribution and Value-Added Services, Global Specialty Products, Global Technology, and Corporate | USD 37 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2024 portion of multi-year 2022 Plan; plan completed as of July 31, 2024. FY2024 charges by segment: GD&VAS $30M; Global Specialty Products $7M; Global Technology $1M; Corporate $(1)M. Primarily severance and employee-related costs plus accelerated amortization and exit costs; related disposal of a U.S. business completed in Q1 2024. Headcount affected not disclosed. | |||
| 2024-12-28 | restructuring | in_progress | 2024-08-06 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 73 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan committed 2024-08-06 to integrate recent acquisitions, right-size operations and increase efficiencies. FY2024 charges of $73M include $13M goodwill/intangible impairment on disposal of a portion of a business. Additional charges expected in 2025; amount not yet determined. No employee count disclosed. | |||
| 2024-12-28 | restructuring | completed | 2022-08-01 | 2024-07-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 37 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Multi-year 2022 Plan completed 2024-07-31; only the FY2024 charge of $37M captured here. Prior-year charges reported in earlier filings. No employee count disclosed. | ||
| 2024-12-28 | acquisition_addition | completed | 2024-04-01 | 2024-04-01 | United States | Global Specialty Products | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquired 60% voting equity interest in TriMed Inc. for $315M consideration; headcount added not disclosed. | |||
| 2024-12-28 | acquisition_addition | completed | 2024-12-28 | 2024-12-28 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Multiple FY2024 acquisitions with total consideration of $113M; ownership interests 51%–100%; headcount added not disclosed. | |||
| 2024-12-28 | divestiture_reduction | completed | 2024-08-06 | 2024-12-28 | Global | Global Specialty Products | USD 13 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Disposal of a portion of a business within Global Specialty Products under the 2024 Plan, with $13M goodwill and intangible impairment; headcount removed not disclosed. | ||
| 2024-12-28 | restructuring | in_progress | 2024-08-06 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Global Technology; Corporate | USD 73 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | 2024 Plan committed August 6, 2024. Charges of $73 million recorded in FY2024 primarily related to severance, accelerated amortization, and impairments. Employee count not explicitly disclosed. | |||
| 2024-12-28 | restructuring | completed | 2022-08-01 | 2024-07-31 | Global | Global Distribution and Value-Added Services; Global Specialty Products; Corporate | USD 37 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | 2022 Plan completed July 31, 2024. Charges of $37 million recorded in FY2024. Employee count not explicitly disclosed. | ||
| 2024-12-28 | restructuring | in_progress | Plan2024 | USD 73,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Plan2022 | USD 37,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 31,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2024 / Global Technology | USD 6,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2024 / Global Distribution And Value Added Services | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2024 / Global Specialty Products | USD 3,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2024 / Global Technology | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Accelerated Depreciation And Amortization / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Distribution And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Distribution And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Specialty Products | USD 15,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Facility Closing / Plan2024 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Facility Closing / Plan2024 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Distribution And Value Added Services | USD 38,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Specialty Products | USD 23,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2024 / Global Technology | USD 10,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Plan2024 | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2022 / Global Distribution And Value Added Services | USD 18,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2022 / Global Specialty Products | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Severance And Employee Related Costs / Plan2022 / Global Technology | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Severance And Employee Related Costs / Plan2022 | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2022 / Global Distribution And Value Added Services | USD 10,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2022 / Global Specialty Products | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Accelerated Depreciation And Amortization / Plan2022 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Accelerated Depreciation And Amortization / Plan2022 | USD -3,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2022 / Global Distribution And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2022 / Global Specialty Products | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Exit And Other Related Costs / Plan2022 / Global Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Exit And Other Related Costs / Plan2022 | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2022 / Global Distribution And Value Added Services | USD 30,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2022 / Global Specialty Products | USD 7,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Plan2022 / Global Technology | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment / Plan2022 | USD -1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Global Distribution And Value Added Services | USD 68,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Global Specialty Products | USD 30,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Operating Segments / Global Technology | USD 11,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | Corporate Non Segment | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-12-28 | restructuring | in_progress | USD 110,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2024-09-28 | restructuring | in_progress | 2024-08-06 | Not specified | Health Care Distribution | USD 29 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan committed to integrate recent acquisitions, right-size operations and increase efficiencies; charges comprise severance, accelerated depreciation/amortization and exit costs. No employee count disclosed; further charges expected in Q4 2024 and 2025 with amount not yet determined. Charge shown is for the three months ended September 28, 2024 (identical to year-to-date). | |||
| 2024-09-28 | restructuring | in_progress | 2024-08-06 | Not specified | Technology and Value-Added Services | USD 7 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Same 2024 Plan program as the Health Care Distribution record, presented by segment in the footnote. No employee count disclosed. Charge shown is for the three months ended September 28, 2024 (identical to year-to-date). | |||
| 2024-09-28 | restructuring | completed | 2022-08-01 | 2024-07-31 | Not specified | Consolidated (both reportable segments) | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2022 Plan (BOLD+1 strategic plan, streamlining and efficiency initiatives) completed July 31, 2024; residual charges of $12 million recorded in the quarter ($37 million year-to-date), primarily severance, accelerated amortization of right-of-use lease assets and exit costs. No employee count disclosed; immaterial charges expected for the remainder of 2024. | ||
| 2024-09-28 | restructuring | in_progress | 2024-08-06 | Global | Health Care Distribution; Technology and Value-Added Services | USD 36 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan announced Aug 6, 2024 to integrate acquisitions and right-size operations. Q3 charges of $36M primarily for severance, accelerated amortization, and lease exit costs. Completion estimate not determined. | |||
| 2024-09-28 | restructuring | completed | 2022-08-01 | 2024-07-31 | Global | Health Care Distribution; Technology and Value-Added Services | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2022 Plan completed July 31, 2024. Q3 charges of $12M primarily for severance and exit costs. | ||
| 2024-09-28 | restructuring | in_progress | USD 48,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2024-09-28 | restructuring | in_progress | Plan2022 | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Plan2024 | USD 36,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 / Health Care Distribution | USD 26,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 / Technology And Value Added Services | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2024 | USD 31,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2024 / Health Care Distribution | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2024 / Technology And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2024 | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2024 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Plan2024 / Health Care Distribution | USD 29,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Plan2024 / Technology And Value Added Services | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2022 / Health Care Distribution | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2022 / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Severance And Employee Related Costs / Plan2022 | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2022 / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2022 / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Accelerated Depreciation And Amortization / Plan2022 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2022 / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2022 / Technology And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Exit And Other Related Costs / Plan2022 | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Plan2022 / Health Care Distribution | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Plan2022 / Technology And Value Added Services | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Health Care Distribution | USD 38,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-09-28 | restructuring | in_progress | Technology And Value Added Services | USD 10,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | 2022-08-01 | 2024-07-31 | Global | Health Care Distribution; Technology and Value-Added Services | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2022 Plan; no employee count disclosed. Company expects $12M of additional charges during remainder of 2024; $15M recorded in Q2 2024 and $25M YTD 2024 (severance, accelerated depreciation/amortization, lease exit costs). Plan completed as of 2024-07-31. | ||
| 2024-06-29 | restructuring | announced | 2024-08-06 | Global | Not specified | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2024 Plan to integrate recent acquisitions, right-size operations and increase efficiencies; charges expected in H2 2024 and 2025 but amount not yet determined; no employee count disclosed. | ||||
| 2024-06-29 | acquisition_addition | completed | 2024-04-01 | United States | Health Care Distribution (orthopedic products) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 60% voting equity interest in TriMed Inc. for $316M total consideration; acquired headcount not disclosed. | ||||
| 2024-06-29 | restructuring | in_progress | 2022-08-01 | 2024-07-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 25 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2022 Plan focused on funding BOLD+1 strategic plan priorities. Completed as of July 31, 2024. Q2 2024 charges included severance, accelerated amortization, and lease exit costs. | ||
| 2024-06-29 | restructuring | announced | 2024-08-06 | Global | Global | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | 2024 Plan announced August 6, 2024 to integrate recent acquisitions and right-size operations. Charges expected in H2 2024 and 2025; amount not yet determined. | ||||
| 2024-06-29 | restructuring | in_progress | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2024-06-29 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Severance And Employee Related Costs | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Accelerated Depreciation And Amortization | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Exit And Other Related Costs | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Health Care Distribution | USD 14,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-06-29 | restructuring | in_progress | Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health Care Distribution; Technology and Value-Added Services | USD 10 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | BOLD+1-related restructuring plan, originally committed 2022-08-01 and extended through end of 2024; Q1 2024 charge of $10M primarily severance, accelerated amortization and lease exit costs ($9M Health Care Distribution, $1M Technology); filer states it cannot in good faith estimate total costs; no employee counts disclosed | ||
| 2024-03-30 | acquisition_addition | completed | Not disclosed | Technology and Value-Added Services | USD 19 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Multiple 100%-owned acquisitions completed during the quarter with $19M total consideration; headcount added not disclosed; charge value shown is total acquisition consideration, not a workforce charge | ||||
| 2024-03-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 10 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring plan committed to on August 1, 2022, extended through end of 2024. Q1 2024 charges of $10 million primarily related to severance, employee-related costs, accelerated amortization, and lease exit costs. Employee count not disclosed. | ||
| 2024-03-30 | restructuring | in_progress | USD 10,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2024-03-30 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Severance And Employee Related Costs | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Accelerated Depreciation And Amortization | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Exit And Other Related Costs | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Health Care Distribution | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-03-30 | restructuring | in_progress | Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Health care distribution | USD 72 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Fiscal 2023 restructuring costs under the BOLD+1 plan committed August 1, 2022: $41M severance and employee-related costs, $13M impairment/accelerated amortization of lease and long-lived assets, $5M exit costs, and $13M loss on disposal of a business. Program extended through end of 2024; no estimate of future costs provided. Accrued restructuring liability of $22M at fiscal year-end, primarily severance. | |||
| 2023-12-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Technology and value-added services | USD 8 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Fiscal 2023 restructuring costs under the same BOLD+1 plan: $5M severance and employee-related costs, $2M impairment/accelerated amortization, and $1M exit costs. Accrued restructuring liability of $1M at fiscal year-end. | |||
| 2023-12-30 | divestiture_reduction | in_progress | 2024-12-31 | Non-U.S. (country not specified) | Health care distribution | USD 12 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Planned disposal of a non-U.S. business; $12M intangible asset impairment recorded in fiscal 2023, included within the $80M restructuring total (not additive). Expected completion during 2024. | |||
| 2023-12-30 | divestiture_reduction | completed | United States | Health care distribution | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Disposal of a non-profitable U.S. business initiated in fiscal 2022 ($49M of costs recorded in fiscal 2022) and completed during the first quarter of fiscal 2023. | |||||
| 2023-12-30 | acquisition_addition | completed | 2023-10-02 | United States | Health care distribution (medical / homecare) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired 90% voting equity interest in Shield Healthcare, Inc., a California-based supplier of homecare medical products delivered directly to patients; employee headcount not disclosed. | ||||
| 2023-12-30 | acquisition_addition | completed | 2023-07-05 | Brazil | Health care distribution (dental) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired 100% voting equity interest in S.I.N. Implant System, a Sao Paulo-based dental implant manufacturer; employee headcount not disclosed. | ||||
| 2023-12-30 | acquisition_addition | completed | 2023-04-05 | France | Health care distribution (dental) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired 57% voting equity interest in Biotech Dental, a provider of dental implants, clear aligners, individualized prosthetics and digital dental software; employee headcount not disclosed. | ||||
| 2023-12-30 | acquisition_addition | completed | Health care distribution and technology and value-added services | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Other fiscal 2023 acquisitions with ownership interests ranging from 51% to 100%; total consideration $284 million; individual employee headcounts not disclosed. | ||||||
| 2023-12-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health care distribution; Technology and value-added services | USD 80 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2023 activity within a program committed 2022-08-01 and extended through end of 2024; $80M total restructuring and integration costs recorded in FY2023, of which $46M was severance and employee-related costs ($41M health care distribution, $5M technology and value-added services). No employees-affected count disclosed; filer states it cannot in good faith estimate total program cost. Includes $12M intangible impairment for a planned non-U.S. business disposal and $13M loss on disposal of a business. | ||
| 2023-12-30 | divestiture_reduction | in_progress | 2024-12-31 | Non-U.S. | Health care distribution | USD 12 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Planned disposal of a non-U.S. business; $12M intangible asset impairment recorded in FY2023 within the $80M restructuring charges. Disposal expected to complete in 2024. Headcount impact not disclosed. | |||
| 2023-12-30 | acquisition_addition | completed | United States; France; Brazil; various | Health care distribution; Technology and value-added services | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2023 acquisitions included Shield Healthcare (2023-10-02, 90% interest), S.I.N. Implant System (2023-07-05), Biotech Dental (2023-04-05, 57% interest), and other acquisitions with ownership interests of 51%-100%. Headcount added through these acquisitions is not disclosed. | |||||
| 2023-12-30 | other | in_progress | 2023-10-01 | North America; Europe | Dental and medical distribution operations | USD 11 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | October 2023 cybersecurity incident disrupted distribution operations and e-commerce; $11M of direct costs (mostly professional fees) incurred in FY2023 for remediation, with expected short-term residual impact in 2024. Not a headcount action per se, but a material workforce-operations disruption; no employee separations disclosed. Insurance: $60M policy following $5M retention. | |||
| 2023-12-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Global | USD 80 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | BOLD+1 strategic plan restructuring initiated Aug 1, 2022. Extended through end of 2024. $80M recorded in FY2023. Filer states: 'currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred... or an estimate of the amount or range of amounts that will result in future cash expenditures.' Employee count not disclosed. | ||
| 2023-12-30 | restructuring | completed | 2019-11-20 | 2021-12-31 | Global | Global | USD 8 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Prior restructuring initiative related to animal health spin-off. Completed in 2021. $8M recorded in FY2021 (comparative). Included for context of multi-year program disclosure, though activity is zero in FY2023. | ||
| 2023-12-30 | restructuring | in_progress | USD 80,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2023-12-30 | restructuring | in_progress | Severance And Employee Related Costs / Healthcare Distribution | USD 41,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Healthcare Distribution | USD 13,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Exit And Other Related Costs / Healthcare Distribution | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Facility Closing / Healthcare Distribution | USD 13,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Healthcare Distribution | USD 72,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Technology And Value Added Services | USD 8,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-12-30 | restructuring | in_progress | Technology | USD 8,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health care distribution; Technology and value-added services | USD 59 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Restructuring plan committed 2022-08-01, now expected to extend through 2024; filer states it cannot in good faith estimate total cost. $59M recorded for the nine months ended 2023-09-30 ($11M in Q3), primarily severance, accelerated amortization and lease exit costs. No employee counts disclosed; accrued restructuring liability was $27M at 2023-09-30. | ||
| 2023-09-30 | acquisition_addition | completed | 2023-07-05 | Brazil | Health care distribution (dental implants manufacturing) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 100% voting equity interest acquired 2023-07-05 for $326M cash; acquired headcount not disclosed. | ||||
| 2023-09-30 | acquisition_addition | completed | 2023-04-05 | France | Health care distribution; Technology and value-added services (dental implants, clear aligners, digital software) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 57% voting equity interest acquired 2023-04-05; total consideration $423M including $182M redeemable noncontrolling interests. Acquired headcount not disclosed. | ||||
| 2023-09-30 | acquisition_addition | completed | Global | Health care distribution; Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Aggregated disclosure of other acquisitions completed during the nine months ended 2023-09-30 (ownership interests 51%-100%, total consideration $283M); individual dates and acquired headcount not disclosed. | |||||
| 2023-09-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 11 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring plan committed to on August 1, 2022, focused on funding strategic priorities and streamlining operations. Expected to extend through 2024. Q3 2023 charges of $11 million primarily related to severance, employee-related costs, accelerated amortization, and lease exit costs. | ||
| 2023-09-30 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 59 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | YTD 2023 charges of $59 million primarily related to severance, employee-related costs, accelerated amortization, and lease exit costs. Includes immaterial amounts related to disposal of an unprofitable U.S. business. | ||
| 2023-09-30 | restructuring | in_progress | USD 11,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2023-09-30 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Health Care Distribution | USD 10,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-09-30 | restructuring | in_progress | Disposal Of Business / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Health care distribution | USD 42 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Six-month charge; Q2 charge was $16M. Severance, accelerated depreciation/amortization, and lease exit costs. No employee counts disclosed; completion extended through 2024 | |||
| 2023-07-01 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Technology and value-added services | USD 6 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Six-month charge; Q2 charge was $2M. No employee counts disclosed | |||
| 2023-07-01 | acquisition_addition | completed | 2023-04-05 | France | Dental technology / dental implants | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 57% voting equity interest; headcount added not disclosed | ||||
| 2023-07-01 | acquisition_addition | completed | Dental technology, medical device, medical distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Aggregated acquisitions during six months ended July 1, 2023 with ownership interests of 51% to 100%; headcount added not disclosed | ||||||
| 2023-07-01 | divestiture_reduction | completed | 2023-03-31 | United States | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Disposal of an unprofitable U.S. business initiated in 2022 and completed in Q1 2023; charge described as immaterial, headcount not disclosed | ||||
| 2023-07-01 | restructuring | in_progress | 2022-08-01 | 2024-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 48 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring plan committed to on August 1, 2022, expected to extend through 2024. YTD charges of $48 million primarily related to severance, accelerated amortization, and lease exit costs. Employee count not disclosed. | ||
| 2023-07-01 | restructuring | in_progress | USD 18,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2023-07-01 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 13,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Severance And Employee Related Costs | USD 14,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Accelerated Depreciation And Amortization | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Exit And Other Related Costs | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Health Care Distribution | USD 16,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Technology And Value Added Services | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Disposal Of Business / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Disposal Of Business / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-07-01 | restructuring | in_progress | Disposal Of Business | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | Global | Health care distribution; Technology and value-added services | USD 30 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Q1 2023 charge of $30M ($26M health care distribution, $4M technology) for severance, accelerated amortization and lease exit costs; includes $1M loss on disposal of an unprofitable U.S. business. Company states it cannot in good faith estimate total program cost. No employee counts disclosed. | ||
| 2023-04-01 | acquisition_addition | completed | Not disclosed | Health care distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of majority of a company completed during Q1 2023; total consideration $11M, goodwill $9M. Headcount added not disclosed; impact described as not material. | |||||
| 2023-04-01 | divestiture_reduction | completed | 2023-04-01 | United States | Not disclosed | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Disposal of an unprofitable U.S. business initiated in 2022 and completed in Q1 2023, with $1M loss on disposal recorded within restructuring costs. Employees affected not disclosed. | |||
| 2023-04-01 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 30 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring plan committed to on August 1, 2022, expected to extend through 2023. Q1 2023 charges of $30 million primarily related to severance, accelerated amortization, and lease exit costs. Employee count not disclosed. | ||
| 2023-04-01 | restructuring | in_progress | USD 30,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2023-04-01 | restructuring | in_progress | Disposal Of Unprofitable Us Business | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 17,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Severance And Employee Related Costs | USD 20,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Accelerated Depreciation And Amortization | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Exit And Other Related Costs | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Disposal Of Business / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Disposal Of Business / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Disposal Of Business | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Health Care Distribution | USD 26,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-04-01 | restructuring | in_progress | Technology And Value Added Services | USD 4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | USD 29 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Company-wide plan to fund strategic priorities and streamline operations, extending through 2023. FY2022 severance and employee-related costs of $29M ($25M health care distribution; $4M technology and value-added services) within total FY2022 restructuring charges of $128M. Total program cost not yet estimable and no employee headcount disclosed; remaining accrued restructuring liability of $24M at year-end. | ||||
| 2022-12-31 | plant_closure | completed | 2022-08-01 | 2022-12-31 | Melville, New York, United States | Corporate headquarters | USD 34 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | One building at the corporate headquarters was vacated during the three months ended December 31, 2022 under the August 2022 restructuring plan, resulting in accelerated amortization of a right-of-use lease asset (within the $47M impairment/accelerated D&A restructuring category); no associated headcount disclosed. | ||
| 2022-12-31 | divestiture_reduction | in_progress | 2022-12-31 | 2023-03-31 | United States | Health care distribution | USD 49 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Disposal of a non-profitable US business initiated during the three months ended December 31, 2022 as part of the August 2022 restructuring plan; expected completion in Q1 2023. Costs primarily comprise intangible asset and goodwill impairments (including $20M goodwill impairment and $15M intangible impairment per Note 7), inventory impairment, and severance and employee-related costs; no employee count disclosed. | ||
| 2022-12-31 | acquisition_addition | completed | 2022-08-26 | Health care distribution | USD 3 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition of Midway Dental Supply completed August 26, 2022; integration costs of $3M for one-time employee and other costs. Related restructuring charges of $9M are included within the $128M FY2022 restructuring charges (not additive to the restructuring plan record). Headcount added through the acquisition was not disclosed. | ||||
| 2022-12-31 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | Global | Company-wide | USD 128 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2022 charges under the plan committed 2022-08-01, expected to extend through 2023; includes $29M severance and employee-related costs, $47M impairment and accelerated ROU amortization (including $34M for vacating a Melville NY headquarters building), $3M exit costs, and $49M loss on disposal of an unprofitable U.S. business (expected to complete Q1 2023). Employees affected not disclosed. An additional $3M of integration costs (Midway Dental Supply) brings total restructuring and integration costs to $131M. | ||
| 2022-12-31 | acquisition_addition | completed | 2022-08-26 | United States | Health care distribution | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Midway Dental Supply acquired 2022-08-26; $3M integration costs and $9M restructuring charges recorded in FY2022. Headcount added through the acquisition not disclosed; 2022 acquisitions in aggregate were described as immaterial. | ||||
| 2022-12-31 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | Global | Corporate and Operations | USD 128 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Restructuring plan committed August 1, 2022, focused on funding strategic plan priorities and streamlining operations. Charges include severance, accelerated amortization of right-of-use lease assets, impairment of long-lived assets, and lease exit costs. Expected to extend through 2023. Employee count not explicitly disclosed. | ||
| 2022-12-31 | restructuring | in_progress | 2022-08-26 | United States | Health Care Distribution | USD 9 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Restructuring charges related to the acquisition of Midway Dental Supply. Includes one-time employee and other costs. Employee count not explicitly disclosed. | |||
| 2022-12-31 | plant_closure | completed | 2022-12-31 | 2022-12-31 | United States | Corporate | USD 34 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Vacated one of the buildings at corporate headquarters in Melville, NY, resulting in accelerated amortization of right-of-use lease asset. Employee count not explicitly disclosed. | ||
| 2022-12-31 | divestiture_reduction | in_progress | 2022-12-31 | 2023-03-31 | United States | Health Care Distribution | USD 49 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiated disposal of a non-profitable US business. Costs include impairment of intangible assets and goodwill, inventory impairment, and severance. Disposal expected to be completed in Q1 2023. Employee count not explicitly disclosed. | ||
| 2022-12-31 | restructuring | in_progress | USD 128,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2022-12-31 | restructuring | in_progress | Facility Closing | USD 49,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Midway Dental Supply | USD 9,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Severance And Employee Related Costs / Healthcare Distribution | USD 25,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Impairment And Accelerated Depreciation And Amortization / Healthcare Distribution | USD 47,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Exit And Other Related Costs / Healthcare Distribution | USD 3,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Facility Closing / Healthcare Distribution | USD 49,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Healthcare Distribution | USD 124,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Technology And Value Added Services | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-12-31 | restructuring | in_progress | Technology | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | North America | Health Care Distribution | USD 9 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan covers severance, office-space rationalization in North America tied to remote work, and efficiency initiatives; charges comprise $6M severance, $2M accelerated depreciation/amortization, $1M exit costs, and include $2M restructuring related to the Midway Dental Supply acquisition. Number of employees affected not disclosed; company states it cannot in good faith estimate total costs. A separate $1M of integration costs was recorded in the quarter. | ||
| 2022-09-24 | acquisition_addition | completed | 2022-08-26 | Health Care Distribution | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Midway Dental Supply acquired August 26, 2022; headcount added not disclosed. Related $1M integration costs and $2M restructuring charges are already included in the restructuring record above and are not counted again here. | |||||
| 2022-09-24 | restructuring | in_progress | 2022-08-01 | 2023-12-31 | North America | Corporate / General | USD 9 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Plan focused on streamlining operations and rationalizing office space due to remote work transition. Charges primarily related to severance, employee-related costs, and lease exit costs. Employee count not disclosed. | ||
| 2022-09-24 | acquisition_addition | completed | 2022-08-26 | North America | Health Care Distribution | USD 1 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Midway Dental Supply. Integration costs of $1 million recorded for one-time employee and other costs. Headcount added not disclosed. | |||
| 2022-09-24 | restructuring | in_progress | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2022-09-24 | restructuring | in_progress | Midway Dental Supply | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Severance And Employee Related Costs / Health Care Distribution | USD 6,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Severance And Employee Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Accelerated Depreciation And Amortization / Health Care Distribution | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Accelerated Depreciation And Amortization / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Exit And Other Related Costs / Health Care Distribution | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Exit And Other Related Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Integration Employee Related And Other Costs / Health Care Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Integration Employee Related And Other Costs / Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Health Care Distribution | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-09-24 | restructuring | in_progress | Technology And Value Added Services | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2022-06-25 | restructuring | announced | 2022-08-01 | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter plan to fund strategic priorities and streamline operations; charges expected in 2022 and 2023, primarily severance and facility-related costs, amount not yet determined. Also disclosed in Part II, Item 5 (deduplicated here) | ||||||
| 2022-06-25 | restructuring | announced | 2022-08-01 | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Filer committed to a restructuring plan focused on funding strategic priorities and streamlining operations. Charges expected in 2022 and 2023, primarily severance and facility-related costs. Estimate of charges and employee count not yet determined. | ||||||
| 2021-12-25 | restructuring | completed | 2019-11-20 | 2021-12-31 | Health care distribution | USD 5,939 (thousands) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2021 segment-level provision under the multi-year program announced November 20, 2019 to mitigate stranded costs from the Animal Health Spin-off; timeline extended to the end of 2021 due to COVID-19. Charges comprise severance benefits and facility exit costs; no employee count disclosed. Program now complete; only FY2021 activity captured. | |||
| 2021-12-25 | restructuring | completed | 2019-11-20 | 2021-12-31 | Technology and value-added services | USD 2,000 (thousands) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2021 segment-level provision under the same multi-year program announced November 20, 2019; timeline extended to the end of 2021 due to COVID-19. No employee count disclosed. Program now complete; only FY2021 activity captured. | |||
| 2021-12-25 | restructuring | completed | 2019-11-20 | 2021-12-31 | Global | Consolidated (stranded costs from Animal Health Spin-off; operations rationalization) | USD 8 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2021 charge of $7.9M for severance and facility exit costs; program originally slated for 2020, extended to end of 2021 due to COVID-19. Activities now complete with no separate restructuring costs expected in 2022. Employees affected not disclosed; charge covers current fiscal year only. | ||
| 2021-12-25 | restructuring | completed | 2019-11-20 | 2021-12-31 | Global | All segments | USD 8 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Initiative committed Nov 2019 to mitigate stranded costs from Animal Health Spin-off and rationalize operations. Extended to end of 2021 due to COVID-19. Activities now complete. Charge includes severance and facility exit costs. Employee count not disclosed. | ||
| 2021-09-25 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | USD 3 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program to mitigate stranded costs from the Animal Health spin-off and rationalize operations; extended to end of 2021 due to COVID-19. Charge shown is nine months ended 2021-09-25 (Q3 alone was a $0.2M credit). No employee counts disclosed; filer states it cannot in good faith estimate remaining 2021 amounts. | ||||
| 2021-09-25 | acquisition_addition | completed | Health care distribution; Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Multiple acquisitions completed during the nine months ended 2021-09-25 (initial ownership 51%–100%); total consideration $614.3M including $435.2M cash. No headcount added disclosed. Separately, Item 4 notes Q3 acquisitions of medical and dental businesses with combined annual revenues of about $165 million. | ||||||
| 2021-09-25 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 3 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative intended to mitigate stranded costs from Animal Health Spin-off and rationalize operations. Extended to end of 2021 due to COVID-19. Filer unable to estimate total cost or employee count. | ||
| 2021-06-26 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health care distribution; Technology and value-added services | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program committed 2019-11-20 to mitigate stranded costs from the Animal Health Spin-off and rationalize operations; completion extended from end of 2020 to end of 2021 due to COVID-19. Filer discloses no employee count. Severance provision: $0.6M in Q2 2021 and $3.5M YTD 2021 (severance, facility exit and other costs); accrued restructuring balance $3.6M at 2021-06-26. Filer states it cannot in good faith estimate total 2021 costs. Segment split of YTD provision: Health care distribution $3.1M, Technology and value-added services $0.5M. | ||
| 2021-06-26 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative to mitigate stranded costs from Animal Health Spin-off and rationalize operations. Extended to end of 2021 due to COVID-19. YTD charges include severance and facility exit costs. Employee count not disclosed. | ||
| 2021-03-27 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health care distribution | USD 3 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program committed 2019-11-20 to mitigate stranded costs from the Animal Health Spin-off and rationalize operations; extended to end of 2021 due to COVID-19. Charge shown is the Q1 2021 provision for the health care distribution segment (2,803 thousand); no employee counts disclosed. Remaining accrued balance at 2021-03-27 for this segment was 7,096 thousand. | ||
| 2021-03-27 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Technology and value-added services | USD 0 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Same restructuring program as the health care distribution record; charge shown is the Q1 2021 provision for this segment (128 thousand). No employee counts disclosed. Remaining accrued balance at 2021-03-27 for this segment was 238 thousand. | ||
| 2021-03-27 | acquisition_addition | completed | North America and Europe | Health care distribution; Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Multiple immaterial acquisitions completed during Q1 2021 (aggregate consideration 289.0 million, including 213.8 million cash and 75.2 million redeemable noncontrolling interests; goodwill 95.3 million); acquired businesses had approximate aggregate annual revenues of 354 million per Item 4. No headcount added through these acquisitions is disclosed. | |||||
| 2021-03-27 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health Care Distribution and Technology and Value-Added Services | USD 3 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed to in Nov 2019 to mitigate stranded costs from Animal Health Spin-off and rationalize operations. Extended to end of 2021 due to COVID-19. Q1 2021 charges of $2.9M included severance and facility exit costs. Employee count not disclosed. | ||
| 2020-12-26 | restructuring | in_progress | 2019-11-20 | Global | Health care distribution | USD 31 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2020 provision of $30.9M of the $32.1M total; company-wide 2020 components were severance $25.8M, facility closing costs $5.9M and other $0.4M. The combined 2020 provision covers continuing activity under both the July 2018 and November 2019 initiatives; the November 2019 initiative (stranded-cost mitigation after the Animal Health Spin-off) was originally expected to finish by end of 2020 but continues into 2021 due to COVID-19, and 2021 costs are stated as not estimable. No employee count for FY2020 activity is disclosed. | |||
| 2020-12-26 | restructuring | in_progress | 2019-11-20 | Global | Technology and value-added services | USD 1 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2020 provision of $1.2M of the $32.1M total restructuring charge. Program was originally expected to complete by end of 2020; extended into 2021 due to COVID-19, with 2021 costs not estimable. No employee count for FY2020 activity is disclosed. | |||
| 2020-12-26 | restructuring | in_progress | 2019-11-20 | 2021-12-31 | Global | Health care distribution; Technology and value-added services | USD 32 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2020 charge of $32.1M (severance $25.8M, facility closing $5.9M, other $0.4M); program committed 2019-11-20 to mitigate Animal Health spin-off stranded costs and rationalize operations, extended into 2021 due to COVID-19; employees affected not disclosed; FY2020 activity only | ||
| 2020-12-26 | acquisition_addition | completed | Global | Health care distribution; Technology and value-added services | USD 58 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Aggregate 2020 acquisitions consideration of $57.8M, described as immaterial individually; headcount added through acquisitions not disclosed | ||||
| 2020-12-26 | restructuring | in_progress | 2018-07-09 | Global | Global | USD 32 (thousands) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018 to rationalize operations. Fiscal 2020 charges of $32.1 million primarily for severance ($25.8 million) and facility closing ($5.9 million). Activities continued into 2021 due to COVID-19. | |||
| 2020-12-26 | restructuring | in_progress | 2019-11-20 | Global | Global | USD 0 (thousands) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Initiative committed Nov 20, 2019 to mitigate stranded costs from Animal Health Spin-off. No specific charge attributed solely to this initiative in the 2020 footnote table, but activities continued into 2021. | |||
| 2020-09-26 | restructuring | in_progress | 2019-11-20 | Global | Health care distribution; Technology and value-added services | USD 28 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Consolidated provision for nine months ended 2020-09-26 covers both the July 9, 2018 cost-reduction initiative and the November 20, 2019 initiative (stranded costs from Animal Health Spin-off plus operational rationalization); includes severance and facility exit costs. No employee counts disclosed. Original completion by end of 2020 is being re-assessed due to COVID-19. Accrued restructuring balance at 2020-09-26 was $15.3 million. | |||
| 2020-09-26 | other | in_progress | 2020-03-01 | Global | Corporate and field operations | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Temporary COVID-19 cost-reduction measures included certain payroll reductions, sharply lower capital expenditures and reduced corporate spending; most temporary expense-reduction initiatives ended during Q3 2020 as markets recovered. No headcount figures quantified. | ||||
| 2020-09-26 | restructuring | in_progress | 4% | 2018-07-09 | Global | All segments | USD 28 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed to July 9, 2018, resulted in elimination of approx 4% of workforce. YTD 2020 charges of $27.7M include severance and facility exit costs. | ||
| 2020-09-26 | restructuring | in_progress | 2019-11-20 | Global | All segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed Nov 20, 2019 to mitigate stranded costs from Animal Health Spin-off. Timeline reassessed due to COVID-19. Included in total YTD charges. | ||||
| 2020-06-27 | restructuring | in_progress | 2018-07-09 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Operational rationalization and expense-efficiency initiative; filing states it eliminated approximately 4% of workforce and closed certain facilities (cumulative, since 2018). No employee count or program-specific charge disclosed for the current period; aggregate restructuring costs were $15.9M (Q2) and $20.7M (six months) across all programs | ||||
| 2020-06-27 | restructuring | in_progress | 2019-11-20 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Initiative to mitigate stranded costs from the Animal Health Spin-off and rationalize operations; originally targeted for completion by end of 2020, but timeline is being re-assessed due to COVID-19. Severance accrual balance was $16.2M at 2020-06-27; no employee count or program-specific charge disclosed | ||||
| 2020-06-27 | other | in_progress | Global | Company-wide | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | COVID-19 cost-reduction measures including payroll reductions, furloughs, reduced pay and hours, voluntary unpaid time off, suspension of 401(k) match, and job reductions; some customer-facing staff restored from furlough as markets recovered. No counts quantified; announcement date not specified | |||||
| 2020-06-27 | restructuring | in_progress | 2018-07-09 | Global | All segments | USD 21 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018 to rationalize operations. YTD 2020 charge of $20.7 million includes severance and facility exit costs. No specific employee count disclosed for current period activity. | |||
| 2020-06-27 | restructuring | in_progress | 2019-11-20 | Global | All segments | USD 21 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed Nov 20, 2019 to mitigate stranded costs from Animal Health Spin-off. Timeline reassessed due to COVID-19. Charges included in the consolidated $20.7 million YTD total. | |||
| 2020-06-27 | other | in_progress | 2020-03-01 | Global | All segments | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Cost reduction measures implemented due to COVID-19 including payroll reductions, furloughs, reduced pay, and work hours. Some workforce restored in customer-facing roles as markets recovered. | ||||
| 2020-03-28 | restructuring | in_progress | 2019-11-20 | Global | Company-wide | USD 5 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program to mitigate stranded costs from the Animal Health Spin-off and rationalize operations; originally targeted for completion end of 2020, timeline being re-assessed due to COVID-19. $4.8M is the total Q1 2020 restructuring provision across all programs, not allocated between programs; no employee counts disclosed. | |||
| 2020-03-28 | restructuring | in_progress | 2018-07-09 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Cost-efficiency initiative that previously eliminated approximately 4% of the workforce and closed certain facilities; ongoing with a $9.966M accrued balance at quarter-end. No current-quarter headcount impact disclosed. | ||||
| 2020-03-28 | acquisition_addition | completed | Health care distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Q1 2020 acquisitions totaling $36.2M consideration (individually immaterial), including a European dental business with ~$25M annual revenue per Item 4; no headcount added disclosed. | ||||||
| 2020-03-28 | restructuring | announced | Global | Company-wide | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | COVID-19 cost-reduction measures including certain payroll reductions, sharply lower capital expenditures and reduced corporate spending; no employee counts or announcement date given (disclosed in the 10-Q filed 2020-05-05). | |||||
| 2020-03-28 | other | announced | 1 | 2020-04-06 | 2020-06-30 | United States | Executive (Chairman and CEO) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter: Chairman/CEO voluntarily waived 100% of base salary (less benefit contributions) from 2020-04-06 through 2020-06-30 in response to COVID-19; salary deemed unchanged for incentive and severance purposes. | ||
| 2020-03-28 | restructuring | in_progress | 2018-07-09 | Global | Health Care Distribution | USD 5 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed to July 9, 2018 to rationalize operations. Q1 2020 provision of $4.7M total includes $4.7M for Health Care Distribution. Employee count not disclosed for current quarter activity. | |||
| 2020-03-28 | restructuring | in_progress | 2018-07-09 | Global | Technology and Value-Added Services | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed to July 9, 2018 to rationalize operations. Q1 2020 provision of $4.7M total includes $0.1M for Technology and Value-Added Services. Employee count not disclosed for current quarter activity. | |||
| 2020-03-28 | restructuring | in_progress | 2019-11-20 | Global | Global | USD 5 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed to Nov 20, 2019 to mitigate stranded costs from Animal Health Spin-off. Total Q1 2020 provision was $4.8M. Filer is re-assessing timeline due to COVID-19. Employee count not disclosed. | |||
| 2019-12-28 | restructuring | completed | 4% | 2018-07-09 | USD 15 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year initiative (2018–2019) to rationalize operations; eliminated approximately 4% of workforce program-wide and closed certain facilities. Fiscal 2019 charge of $14.7 million, primarily severance ($13.7M) plus facility closing ($0.9M); by segment, 2019 provision was $13.9M health care distribution and $0.8M technology and value-added services. Accrued restructuring balance of $13.8M remained at fiscal year-end. Prior-year (2018) charge of $54.4M excluded. | ||||
| 2019-12-28 | restructuring | announced | 2019-11-20 | 2020-12-31 | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Committed initiative to mitigate stranded costs from the Animal Health Spin-off and rationalize operations; company stated it was unable to estimate costs or employees affected; activities expected to be completed by end of 2020. | |||||
| 2019-12-28 | divestiture_reduction | completed | 2019-02-07 | Animal Health (discontinued operations) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Separation and merger of the animal health business with Vets First Choice (forming Covetrus) completed on the February 7, 2019 Distribution Date; headcount of the divested business not disclosed. Company received a $1,120 million tax-free distribution plus $361.1 million from a share sale. | |||||
| 2019-12-28 | restructuring | in_progress | 2018-07-09 | Global | Company-wide | USD 15 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2019 charge of $14.7M under the program committed July 9, 2018 (severance $13.8M, facility closing $0.9M); program cumulatively eliminated approximately 4% of workforce, primarily in FY2018. Employees affected in FY2019 not separately disclosed. | |||
| 2019-12-28 | restructuring | announced | 2019-11-20 | 2020-12-31 | Global | Company-wide | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Intended to mitigate stranded costs from the Animal Health spin-off and rationalize operations; company stated it could not in good faith estimate the charge or headcount impact. | |||
| 2019-12-28 | divestiture_reduction | completed | 2019-02-07 | 2019-02-07 | Global | Henry Schein Animal Health Business | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Animal Health business separated and merged with Vets First Choice to form Covetrus on the Distribution Date; associated workforce transferred not disclosed. FY2019 discontinued-operations net sales of $319.5M reflect activity through the Distribution Date. | |||
| 2019-12-28 | acquisition_addition | completed | Global | Health care distribution; Technology and value-added services | USD 653 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Aggregate consideration for fiscal 2019 acquisitions, individually immaterial; individual transaction dates and headcount added not disclosed. | ||||
| 2019-12-28 | restructuring | completed | 4% | 2018-07-09 | 2019-12-28 | Global | All segments | USD 15 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018 to rationalize operations. Resulted in elimination of approximately 4% of workforce. $14.7 million costs recorded in 2019. | |
| 2019-12-28 | restructuring | announced | 2019-11-20 | 2020-12-31 | Global | All segments | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative committed Nov 20, 2019 to mitigate stranded costs from Animal Health Spin-off. Expected completion by end of 2020. No estimate of employees affected or costs provided. | |||
| 2019-09-28 | restructuring | completed | 2018-07-09 | 2019-06-29 | Global | Health Care Distribution | USD 15 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program-level reduction equaled approximately 4% of the workforce (count not disclosed) plus certain facility closures; headcount was not broken out by segment. Charge shown is the nine-months 2019 provision for this segment; program costs from continuing operations totaled $54.4M in 2018. Filer states the activities were complete as of June 29, 2019 with no further charges expected in 2019; the current quarter recorded a net credit of $0.8M. | ||
| 2019-09-28 | restructuring | completed | 2018-07-09 | 2019-06-29 | Global | Technology and Value-Added Services | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Segment component of the same company-wide restructuring program announced July 9, 2018; charge shown is the nine-months 2019 provision. Headcount affected was not disclosed by segment. | ||
| 2019-09-28 | divestiture_reduction | completed | 2019-02-07 | 2019-02-07 | Global | Henry Schein Animal Health Business | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Animal Health separation and merger with Vets First Choice completed on the Distribution Date; the business is presented as a discontinued operation. No employee count associated with the transfer is disclosed. | |||
| 2019-09-28 | acquisition_addition | completed | 2019-03-04 | 2019-03-04 | United States | Health Care Distribution (Medical) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of North American Rescue, described as having annual sales of approximately $184 million; no headcount acquired is disclosed. | |||
| 2019-09-28 | acquisition_addition | completed | 2019-03-18 | 2019-03-18 | United States | Technology and Value-Added Services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Henry Schein One subsidiary acquired Lighthouse 360, described as having annual sales of approximately $50 million; no headcount acquired is disclosed. | |||
| 2019-09-28 | restructuring | completed | 4% | 2018-07-09 | 2019-06-29 | Global | All segments | USD 16 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018 to rationalize operations. Resulted in elimination of approximately 4% of workforce and closing of certain facilities. Activities complete as of June 29, 2019. YTD 2019 charge of $15.8 million recorded. | |
| 2019-06-29 | restructuring | completed | 4% | 2018-07-09 | 2019-06-29 | USD 17 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Initiative committed July 9, 2018 to rationalize operations; involved elimination of approximately 4% of workforce and facility closures. Charge shown is the six months ended June 29, 2019 provision ($11.9 million in the quarter), split $15.9M health care distribution and $0.7M technology. Filer states restructuring activities are complete as of June 29, 2019 with no further charges expected for the remainder of 2019; no absolute headcount of employees affected is disclosed. | |||
| 2019-06-29 | divestiture_reduction | completed | 2019-02-07 | 2019-02-07 | Global | Henry Schein Animal Health Business | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Animal Health Spin-off completed on the Distribution Date (February 7, 2019); business presented as discontinued operations for all periods. Assets of $2.29 billion and liabilities of $1.74 billion transferred to Covetrus; no employee counts associated with the separation are disclosed. | |||
| 2019-06-29 | acquisition_addition | completed | 2019-03-04 | United States | Health care distribution (medical) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of North American Rescue, a survivability and casualty-care medical products provider with annual sales of approximately $184 million; $158.8 million of goodwill recorded. No headcount disclosed. | ||||
| 2019-06-29 | acquisition_addition | completed | 2019-03-18 | United States | Technology and value-added services (Henry Schein One) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Henry Schein One subsidiary acquired Lighthouse 360, a dental practice management and patient communication software provider with annual sales of approximately $50 million; $143.4 million of goodwill recorded. No headcount disclosed. | ||||
| 2019-06-29 | restructuring | completed | 4% | 2018-07-09 | 2019-06-29 | Global | All segments | USD 17 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018. Eliminated approx 4% of workforce. Activities complete as of June 29, 2019. YTD 2019 charge $16.6M. | |
| 2019-06-29 | restructuring | in_progress | USD 11,925,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2019-06-29 | restructuring | in_progress | Strategic Plan2018 To2020 | USD 11,900,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-06-29 | restructuring | in_progress | Employee Severance | USD 15,517,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-06-29 | restructuring | in_progress | Facility Closing | USD 947,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-06-29 | restructuring | in_progress | Other Restructuring | USD 102,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-06-29 | restructuring | in_progress | Healthcare Distribution | USD 15,887,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-06-29 | restructuring | in_progress | Technology | USD 679,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | 2018-07-09 | Global | Health care distribution; Technology and value-added services | USD 5 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Q1 2019 provision of $4.6M for redundancies; no employee count disclosed for the current quarter. 2018 program targeted elimination of ~2%-3% of workforce; filer states restructuring will continue in H1 2019 but cannot estimate additional 2019 costs | |||
| 2019-03-30 | divestiture_reduction | completed | 2019-02-07 | 2019-02-07 | Global | Henry Schein Animal Health Business (discontinued operations) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Separation and merger of animal health business with Vets First Choice completed on Distribution Date; no headcount removed disclosed. Approximate annual revenues of $3.7 billion per Item 4 | |||
| 2019-03-30 | acquisition_addition | completed | 2019-03-04 | 2019-03-04 | United States | Health care distribution (medical) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of North American Rescue, annual sales of approximately $184 million; no headcount added disclosed | |||
| 2019-03-30 | acquisition_addition | completed | 2019-03-18 | 2019-03-18 | United States | Technology and value-added services (Henry Schein One) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Henry Schein One acquired Lighthouse 360, annual sales of approximately $50 million; no headcount added disclosed | |||
| 2019-03-30 | restructuring | in_progress | 2018-07-09 | Global | Corporate / All Segments | USD 5 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative committed July 9, 2018 to rationalize operations. Expected to eliminate 2-3% of workforce. Q1 2019 charge of $4.6M recorded for redundancies. Specific headcount affected in Q1 not disclosed. | |||
| 2019-03-30 | restructuring | in_progress | Healthcare Distribution | USD 3,806,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | Facility Closing | USD 155,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | Technology | USD 835,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | Other Restructuring | USD 24,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | Employee Severance | USD 4,462,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2019-03-30 | restructuring | in_progress | USD 4,641,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2019-03-30 | restructuring | in_progress | Strategic Plan2018 To2020 | USD 4,600,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | 2018-07-09 | 2019-06-30 | USD 63 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Initiative committed July 9, 2018 to rationalize operations and reduce costs under the 2018-2020 strategic plan; comprises elimination of approximately 2 to 3 percent of workforce plus closure of certain facilities (no absolute headcount or facility list disclosed, so affected-employee fields left null). Full-year 2018 charge of $62.9 million, primarily severance ($58.2M severance, $3.6M facility closing, $1.1M other); initial estimate was $45-55 million before an additional $35.4 million Q4 2018 charge. Remaining restructuring activities and costs expected during Q1 and Q2 2019 (completion date approximated as end of H1 2019). 2018 charges by segment: health care distribution $59.1 million, technology and value-added services $3.8 million; restructuring accrual balance $32.6 million at December 29, 2018. Separate 2014-announced program (~900 positions, completed 2016) had no 2018 provision and is excluded. | ||||
| 2018-12-29 | divestiture_reduction | completed | 2018-04-20 | 2019-02-07 | Henry Schein Animal Health Business (animal health operating segment within health care distribution) | subsequent_events f5-10k / GLM-5.3-flash-HTML | Separation of the animal health business via contribution to Covetrus and merger with Vets First Choice; completed February 7, 2019, prior to the February 20, 2019 filing date, forming independent Nasdaq-listed Covetrus (CVET). Contribution and merger agreements dated April 20, 2018 per Exhibit 2.3. Divested-business headcount not disclosed, so affected-employee fields left null; animal health results to be reported as discontinued operations from Q1 2019. 2018 spin-off transaction costs of $38.8 million were transaction-related, not workforce severance. | ||||
| 2018-12-29 | restructuring | in_progress | 2018-07-09 | Global | Consolidated (operations rationalization) | USD 63 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program announced 2018-07-09 to eliminate approximately 2% to 3% of workforce and close certain facilities; FY2018 charge of $62.9M (severance $58.2M, facility closing $3.6M, other $1.1M), including a $35.4M Q4 charge from additional cost-savings opportunities. Exact employees affected not disclosed. Company expects to continue restructuring in first half of 2019 and cannot reasonably estimate additional 2019 costs. | |||
| 2018-12-29 | divestiture_reduction | completed | 2018-04-20 | 2019-02-07 | Global | Health care distribution — Henry Schein Animal Health Business | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Separation and merger with Vets First Choice completed 2019-02-07, after fiscal year-end; Covetrus no longer consolidated thereafter. Headcount transferred not disclosed. Related FY2018 transaction costs of $38.8M recorded in operating expenses. | |||
| 2018-12-29 | restructuring | in_progress | 2.5% | 2018-07-09 | Global | All segments | USD 63 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative to rationalize operations and provide expense efficiencies. Expected to include elimination of approximately 2% to 3% of workforce. Full year 2018 charges were $62.9 million, consisting primarily of severance costs. Activities expected to continue in first half of 2019. | ||
| 2018-12-29 | restructuring | in_progress | Technology | USD 3,786,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | Employee Severance | USD 58,154,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | Other Restructuring | USD 1,151,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | USD 35,401,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2018-12-29 | restructuring | in_progress | Healthcare Distribution | USD 59,126,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | Facility Closing | USD 3,607,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-12-29 | restructuring | in_progress | 900 | Restructuring Plan November2014 | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | 2018-07-09 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Initiative to rationalize operations under 2018-2020 strategic plan; expected to eliminate approximately 2% to 3% of workforce and close certain facilities. Expected total 2018 pre-tax costs of $45M to $55M ($0.22 to $0.27 per diluted share); $27.5M recorded in the nine months ended 2018-09-29 ($8.9M in Q3), with $13.5M accrued at quarter-end. No absolute headcount or completion date disclosed. | ||||
| 2018-09-29 | divestiture_reduction | announced | 2018-04-23 | Global | Animal Health | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Planned spin-off of animal health business into Vets First Corp. via merger with Direct Vet Marketing; targeted for end of 2018 or early 2019, subject to regulatory and tax conditions. Expected tax-free cash dividend of $1.0B to $1.25B. No headcount impact disclosed; $18.7M of transaction costs recorded YTD. | ||||
| 2018-09-29 | acquisition_addition | completed | North America | Technology and dental distribution | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Completed acquisition of a technology business and a dental business in North America during the quarter, with approximate aggregate annual revenues of $122 million; headcount added not disclosed. | |||||
| 2018-09-29 | acquisition_addition | completed | 2018-07-01 | Global | Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Closed joint venture with Internet Brands forming Henry Schein One, LLC; company owns 74%, Internet Brands 26% (with earn-out interests up to ~9.2%). Initial goodwill of $412.8M allocated to technology segment; headcount not disclosed. | ||||
| 2018-09-29 | restructuring | in_progress | 2.5% | 2018-07-09 | 2018-12-31 | Global | All segments | USD 50 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative to rationalize operations and provide expense efficiencies. Expected to include elimination of approximately 2% to 3% of workforce and closing of certain facilities. Total 2018 costs expected in range of $45 million to $55 million pre-tax. $27.5 million recorded in first nine months. | |
| 2018-09-29 | restructuring | in_progress | Healthcare Distribution | USD 25,625,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | Restructuring Plan November2014 | USD 27,511,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | USD 8,853,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2018-09-29 | restructuring | in_progress | Employee Severance | USD 26,474,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | Technology | USD 1,886,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | Facility Closing | USD 757,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-09-29 | restructuring | in_progress | Other Restructuring | USD 280,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | announced | 2018-07-09 | Global | Company-wide | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter initiative to rationalize operations under 2018-2020 strategic plan; expected to eliminate approximately 2% to 3% of workforce and close certain facilities. Total 2018 pre-tax costs expected in range of $45 million to $55 million ($0.22 to $0.27 per diluted share), comprising $40-45 million severance and benefits and $5-10 million facility costs. No absolute headcount or completion date disclosed. | ||||
| 2018-06-30 | restructuring | in_progress | Global | Health care distribution; Technology and value-added services | USD 19 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Restructuring costs recorded for certain redundancies: $14.9 million in Q2 2018 and $18.7 million YTD 2018 (severance $17.9M, facility closing $0.6M, other $0.2M provision YTD); accrued balance of $11.6 million at June 30, 2018. No employee counts or announcement date disclosed. | ||||
| 2018-06-30 | divestiture_reduction | announced | 2018-04-23 | 2018-12-31 | Global | Animal health business | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Planned spin-off of animal health business into Vets First Corp. via HS Spinco and merger with Direct Vet Marketing; Henry Schein holders to own ~63% and DVM holders ~37%. Company expects a tax-free cash dividend of $1.0 billion to $1.25 billion. Targeted to close by end of 2018, subject to regulatory and tax conditions. No headcount impact disclosed. | |||
| 2018-06-30 | restructuring | in_progress | 2.5% | 2018-07-09 | 2018-12-31 | Global | All segments | USD 50 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Announced July 9, 2018 (subsequent to quarter end). Expected to eliminate 2% to 3% of workforce. Total costs expected $45M-$55M. $18.7M recorded in Q2 for prior redundancies. | |
| 2018-06-30 | restructuring | in_progress | USD 18,658,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2018-06-30 | restructuring | in_progress | Technology | USD 343,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | in_progress | Other Restructuring | USD 180,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | in_progress | Employee Severance | USD 17,922,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | in_progress | Restructuring Plan November2014 | USD 18,658,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | in_progress | Facility Closing | USD 556,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-06-30 | restructuring | in_progress | Healthcare Distribution | USD 18,315,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Q1 2018 restructuring provision of $3.8M for certain redundancies; no employee count or completion date disclosed. Accrued restructuring balance was $4.0M at quarter end. | ||||||
| 2018-03-31 | restructuring | announced | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Management developing a new restructuring plan, subject to Board approval, considering the planned animal health spin-off and merger; no counts, dates or charges disclosed. | |||||||
| 2018-03-31 | acquisition_addition | completed | Brazil | Animal health | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Brazilian animal health business acquired during the quarter, with approximate annual revenues of $25 million; headcount added not disclosed. | |||||
| 2018-03-31 | divestiture_reduction | announced | 2018-04-23 | 2018-12-31 | Animal health | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement to contribute the animal health business to Spinco and merge with Vets First Choice (Reverse Morris Trust); expected to close by end of 2018. No workforce figures disclosed. | ||||
| 2018-03-31 | other | announced | 2018-04-03 | 2018-06-30 | Technology and value-added services | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Joint venture with Internet Brands forming Henry Schein One (74% Henry Schein / 26% Internet Brands); workforce transferred to the JV not disclosed. Expected to complete in Q2 2018. | ||||
| 2018-03-31 | restructuring | in_progress | 2018-03-31 | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Filer recorded $3.8 million in restructuring costs for certain redundancies. No specific employee count was disclosed for this current period activity. | |||||
| 2018-03-31 | restructuring | in_progress | Other Restructuring | USD 3,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | Technology | USD 118,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | USD 3,762,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2018-03-31 | restructuring | in_progress | Healthcare Distribution | USD 3,644,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | Employee Severance | USD 3,759,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2018-03-31 | restructuring | in_progress | Restructuring Plan November2014 | USD 3,762,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-12-30 | acquisition_addition | completed | 2017-05-02 | United States | Health care distribution — Dental | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Southern Anesthesia and Surgical, Inc. (SAS), a U.S. anesthesia and surgical supplies distributor with 2016 sales of approximately $72 million; $76.5 million of initial goodwill recorded. Headcount added not disclosed. | ||||
| 2017-12-30 | acquisition_addition | completed | 2017-08-28 | United States | Health care distribution — Animal health | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Merritt Veterinary Supplies, Inc., an independent animal health products supplier with 2016 sales of approximately $115 million; $33.4 million of initial goodwill recorded. Headcount added not disclosed. | ||||
| 2017-12-30 | acquisition_addition | completed | Multiple | Multiple | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Additional acquisitions completed during fiscal 2017 described as immaterial individually and in the aggregate, recording approximately $43.9 million of initial goodwill. Headcount added not disclosed. | |||||
| 2017-12-30 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | Global | Corporate / Operations | USD 81 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014, extended through end of 2016. Eliminated approx 900 positions (slightly more than 4% of workforce). Total costs: $34.9M in FY2015 and $45.9M in FY2016. No additional charges in FY2017. |
| 2017-12-30 | restructuring | in_progress | Other Restructuring | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-12-30 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2017-12-30 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-12-30 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-12-30 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-12-30 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-12-30 | restructuring | in_progress | 900 | Restructuring Plan November2014 | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2017-09-30 | acquisition_addition | completed | North America, Europe, Asia, Australia | Animal health; dental | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | During the quarter ended September 30, 2017 the company completed an animal health acquisition in North America and dental acquisitions in Europe, Asia and Australia with approximate aggregate annual revenues of $157.0 million; no headcount added was disclosed. | |||||
| 2017-09-30 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | Global | Corporate / All Segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014, extended through end of 2016. Resulted in elimination of approx 900 positions (4% of workforce). Activities are complete; no charges expected in 2017. | |
| 2017-09-30 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-09-30 | restructuring | in_progress | Other Restructuring | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-09-30 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2017-09-30 | restructuring | in_progress | Restructuring Plan November2014 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-09-30 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-09-30 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-09-30 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Corporate rationalization announced November 2014 and extended through the end of 2016, ultimately eliminating about 900 positions, or 4% of the workforce. Filer states the program is complete with no charges expected in 2017; pre-tax charges were $34.9M in fiscal 2015 and $45.9M in fiscal 2016 (no single program charge disclosed). Remaining severance/facility accrual was $8.5M at July 1, 2017, with $17.2M of payments during the six months then ended. Implied 4% of workforce is consistent with the disclosed headcount of more than 21,000. | |||
| 2017-07-01 | restructuring | completed | 2014-11-06 | 2016-12-31 | Global | Corporate / All Segments | USD 0 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014, extended through end of 2016. Eliminated approx 900 positions (4% of workforce). Activities complete; no charges expected in 2017. Remaining accrued balance of $8.5M as of July 1, 2017. | ||
| 2017-07-01 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2017-07-01 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | in_progress | Restructuring Plan November2014 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | in_progress | Other Restructuring | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-07-01 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | Global | All segments (health care distribution; technology and value-added services) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program eliminated approximately 900 positions (4% of workforce) through end of 2016; filer states activities are complete with no charges expected in 2017. No provision recorded in the current quarter; $11.99M paid during Q1 2017 left a $13.7M accrued balance at 2017-04-01. Prior-period charges: $34.9M (FY2015), $45.9M (FY2016). | |
| 2017-04-01 | restructuring | completed | 2014-11-06 | 2016-12-31 | Global | Corporate / All Segments | USD 0 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014, extended through end of 2016. Eliminated approx 900 positions (4% of workforce). Activities complete; no charges expected in 2017. Remaining accrued balance of $13.7 million as of April 1, 2017. | ||
| 2017-04-01 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2017-04-01 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | in_progress | Restructuring Plan November2014 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2017-04-01 | restructuring | in_progress | Other Restructuring | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | USD 46 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year program announced November 6, 2014 and extended through end of 2016; the ~900 positions eliminated (originally targeted at 2-3% of workforce before extension) is cumulative through fiscal year-end, disclosed as slightly more than 4% of workforce. FY2016 pre-tax charge of $45.9 million comprises severance of $40.7 million, facility closing costs of $3.6 million and other costs of $1.6 million; cumulative program charges were $80.8 million ($34.9 million recorded in fiscal 2015). Restructuring activities complete as of December 31, 2016; no additional charges expected in fiscal 2017. Same action is also described in Item 7 MD&A; extracted once from the footnote. | ||
| 2016-12-31 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | Global | Corporate-wide (facility closings and workforce reduction) | USD 46 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Cumulative through fiscal year-end: ~900 positions eliminated (slightly more than 4% of workforce) since the program's Nov 2014 announcement, extended through end of 2016. FY2016 charge of $45.9M pre-tax (severance $40.7M, facility closing $3.6M, other $1.6M); FY2015 charge was $34.9M. Program declared complete as of 2016-12-31 with no further charges expected in fiscal 2017. |
| 2016-12-31 | acquisition_addition | completed | 2016-01-12 | 2016-01-12 | United States | Animal health — technology (Vetstreet, Inc.) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Purchase of 80.1% interest in Vetstreet, Inc., a veterinary SaaS marketing/analytics provider with 2015 sales of ~$40M; $17.9M initial goodwill. Headcount added not disclosed. | |||
| 2016-12-31 | acquisition_addition | completed | 2016-02-03 | 2016-02-03 | Australia, New Zealand, United Kingdom, Netherlands | Technology and value-added services (RxWorks, Inc.) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of veterinary practice management software provider RxWorks, Inc. (~$7M sales for 12 months ended 2015-06-30); $4.2M initial goodwill. Headcount added not disclosed. | |||
| 2016-12-31 | acquisition_addition | completed | 2016-02-05 | 2016-12-28 | Brazil | Health care distribution — dental (Dental Cremer S.A.) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Majority ownership interest in Brazilian dental distributor Dental Cremer S.A. (~$70M 2015 sales), completed 2016-12-28; $37.5M initial goodwill. Debt of ~$63.8M assumed in 2016 relates primarily to Dental Cremer and Dental Speed Graph. Headcount added not disclosed. | |||
| 2016-12-31 | acquisition_addition | completed | 2016-03-23 | 2016-06-20 | Japan | Health care distribution — dental (One Piece Corp., 50% interest) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 50% interest in One Piece Corp., a subsidiary of J. Morita Corp., with fiscal 2015 aggregate sales of ~$125M. Headcount added not disclosed. | |||
| 2016-12-31 | acquisition_addition | completed | 2016-12-31 | Various | Other acquisitions completed during fiscal 2016 | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Filer states other 2016 acquisitions were immaterial individually and in aggregate, recording ~$69.9M of initial goodwill. Headcount added not disclosed. | ||||
| 2016-12-31 | restructuring | completed | 900 | 4% | 2014-11-06 | 2016-12-31 | Global | Corporate / All Segments | USD 46 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014, extended through end of 2016. Eliminated approx 900 positions (slightly more than 4% of workforce). Total costs to date include $34.9M in FY2015 and $45.9M in FY2016. Activities complete as of Dec 31, 2016. |
| 2016-12-31 | restructuring | in_progress | Other Restructuring | USD 1,576,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | in_progress | Healthcare Distribution | USD 44,082,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | in_progress | USD 45,891,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2016-12-31 | restructuring | in_progress | Technology | USD 1,809,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | in_progress | Employee Severance | USD 40,728,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | in_progress | Facility Closing | USD 3,587,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-12-31 | restructuring | in_progress | 900 | Restructuring Plan November2014 | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | 2014-11-06 | 2016-12-31 | Global | Health care distribution; Technology and value-added services | USD 30 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program targets elimination of approximately 3% to 4% of workforce (headcount number not disclosed); $29.8M pre-tax recorded in nine months ended 2016-09-24 ($5.4M in Q3); accrued balance $19.7M at quarter-end; on 2016-10-28 filer estimated $17M to $22M additional charge in Q4 2016 | ||
| 2016-09-24 | acquisition_addition | completed | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Certain acquisitions completed during nine months ended 2016-09-24, described as immaterial individually and in aggregate; headcount added not disclosed | |||||||
| 2016-09-24 | restructuring | in_progress | 3.5% | 2014-11-06 | 2016-12-31 | Global | All segments | USD 30 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative extended through end of 2016; expected to eliminate 3% to 4% of workforce. $29.8 million pre-tax costs recorded in nine months ended Sept 24, 2016. | |
| 2016-09-24 | restructuring | in_progress | USD 5,370,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2016-09-24 | restructuring | in_progress | Healthcare Distribution | USD 28,963,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | Technology | USD 848,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | Restructuring Plan November2014 | USD 29,811,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | Employee Severance | USD 25,736,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | Facility Closing | USD 2,619,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-09-24 | restructuring | in_progress | Other Restructuring | USD 1,456,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | 2014-11-06 | 2016-12-31 | USD 24 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program announced 2014-11-06 to rationalize operations, involving elimination of approximately 2% to 3% of workforce and closure of certain facilities; originally expected to be completed by end of fiscal 2015. Charge shown is the provision for the six months ended June 25, 2016 ($24.4M pre-tax; $20.4M in Q2 alone); accrued restructuring balance was $21.9M at quarter-end. On 2016-08-04 the company announced restructuring will continue through the end of 2016, with no estimate yet of additional second-half costs. No employee count disclosed. | ||||
| 2016-06-25 | acquisition_addition | completed | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Certain acquisitions were completed during the six months ended June 25, 2016 and were immaterial individually and in the aggregate; no headcount added disclosed. | |||||||
| 2016-06-25 | restructuring | in_progress | 2.5% | 2014-11-06 | 2016-12-31 | Global | Corporate / All Segments | USD 24 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014 to rationalize operations. Includes elimination of approx 2-3% of workforce and facility closures. $24.4M pre-tax costs recorded in six months ended June 25, 2016. Company announced Aug 4, 2016 that activities would continue through end of 2016. | |
| 2016-06-25 | restructuring | in_progress | USD 20,383,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2016-06-25 | restructuring | in_progress | Healthcare Distribution | USD 23,638,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | Technology | USD 803,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | Restructuring Plan November2014 | USD 24,441,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | Employee Severance | USD 20,852,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | Facility Closing | USD 2,460,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-06-25 | restructuring | in_progress | Other Restructuring | USD 1,129,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | 2014-11-06 | 2016-06-30 | USD 46 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Corporate initiative to rationalize operations involving elimination of approximately 2% to 3% of workforce and closing of certain facilities; no absolute headcount disclosed. Total expected pre-tax cost stated as a range of $46M to $49M, of which $34.9M was recorded in fiscal 2015 and $4.1M in Q1 2016; on April 29, 2016 the company estimated $7M to $10M of remaining costs. Completion pushed to the first half of fiscal 2016. Same program also described in MD&A and Part II Item 5 (deduplicated to the footnote). | ||||
| 2016-03-26 | acquisition_addition | completed | 2016-01-12 | Henry Schein Animal Health (health care distribution) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Purchase of an 80.1% interest in Vetstreet, Inc., a SaaS marketing and analytics provider to veterinary practices; no headcount added disclosed. Other Q1 acquisitions described as immaterial individually and in aggregate. | |||||
| 2016-03-26 | acquisition_addition | completed | 2016-02-03 | Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Completed acquisition of RxWorks, Inc., veterinary practice management software provider serving Australia, New Zealand, the UK, the Netherlands and other countries; no headcount added disclosed. | |||||
| 2016-03-26 | acquisition_addition | announced | 2016-03-23 | 2016-06-30 | Japan | Dental (health care distribution) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement with J. Morita Corp. under which Henry Schein will own a 50% interest in One Piece Corp. upon closing, subject to customary conditions; expected to close in Q2 2016. No headcount disclosed. | |||
| 2016-03-26 | restructuring | in_progress | 2.5% | 2014-11-06 | 2016-06-30 | Global | Corporate / All Segments | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014 to eliminate 2-3% of workforce and close facilities. Expected completion extended to first half of fiscal 2016. Total expected costs $46-49 million pre-tax. $4.1 million recorded in Q1 2016. | |
| 2016-03-26 | restructuring | in_progress | Employee Severance | USD 2,597,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | Facility Closing | USD 1,196,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | Other Restructuring | USD 265,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | Healthcare Distribution | USD 3,855,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | Technology | USD 203,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2016-03-26 | restructuring | in_progress | USD 4,058,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2015-12-26 | restructuring | in_progress | 2014-11-06 | 2016-06-30 | USD 35 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Corporate initiative announced November 6, 2014 (in fiscal 2014) to rationalize operations; includes expected elimination of approximately 2% to 3% of the workforce (absolute headcount not disclosed, so percent field left null) and closing of certain facilities. Total program cost expected at $41-47 million pre-tax; the $34.9 million charge recorded in fiscal 2015 comprises $26.7 million severance, $5.7 million facility closing and $2.5 million other costs (by segment: $33.9 million health care distribution, $1.0 million technology and value-added services). Remaining $6-12 million estimated as of February 5, 2016. Completion extended to the first half of fiscal 2016, represented here as end of H1 2016. Only fiscal 2015 activity captured. | ||||
| 2015-12-26 | restructuring | in_progress | 2014-11-06 | 2016-06-30 | Global | Enterprise-wide (corporate initiative) | USD 35 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program announced 2014-11-06 calls for eliminating approximately 2% to 3% of workforce and closing certain facilities; no absolute headcount disclosed. $34.9M pre-tax recorded in FY2015 (severance $26.7M, facility closing $5.7M, other $2.5M); total program cost estimated $41M-$47M pre-tax, with $6M-$12M remaining expected in first half of fiscal 2016. Accrued balance at year-end $12.1M. FY2015 activity only; prior-year activity not extracted. | ||
| 2015-12-26 | acquisition_addition | completed | 2015-03-31 | 2015-03-31 | North America and Europe | Animal health (laboratory and imaging diagnostics distribution) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of scil animal care company GmbH; 2014 annual sales of approximately $83 million; $3.5M initial goodwill. Headcount added not disclosed. | |||
| 2015-12-26 | acquisition_addition | completed | 2015-09-01 | 2015-09-01 | Denmark, Norway, Sweden | Animal health (veterinary supplies distribution) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 85% interest in Jorgen Kruuse A/S; 2014 sales of approximately $90 million; $20.7M initial goodwill. Headcount added not disclosed. | |||
| 2015-12-26 | acquisition_addition | completed | 2015-11-30 | 2015-11-30 | Italy | Dental (consumable merchandise and equipment distribution) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Dental Trey (S.R.L.); sales of approximately $49 million for the 12 months ended 2015-06-30; $8.5M initial goodwill. Headcount added not disclosed. | |||
| 2015-12-26 | acquisition_addition | completed | 2015-12-26 | 2015-12-26 | Various | Health care distribution and technology | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Other acquisitions completed during FY2015, described as immaterial individually and in the aggregate, generating approximately $27.1M of initial goodwill. Headcount added not disclosed. | |||
| 2015-12-26 | other | completed | 2015-06-27 | 2015-06-27 | Romania | Animal health distribution | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 50% non-consolidating ownership investment in Maravet S.A. announced 2015-07-10 as made during the quarter ended 2015-06-27; company had annual sales of approximately $23 million. Not consolidated, so headcount not added to reported totals. | |||
| 2015-12-26 | acquisition_addition | announced | 2016-02-05 | Brazil | Dental (supplies and equipment distribution) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Subsequent event: agreement to acquire a majority ownership interest in Dental Cremer S.A. (Cremer S.A. dental distribution business, Blumenau, Brazil), 2015 sales of approximately $70 million; announced after fiscal year-end and before the 2016-02-10 filing date. Headcount added not disclosed. | ||||
| 2015-12-26 | restructuring | in_progress | 2.5% | 2014-11-06 | 2016-06-30 | Global | Corporate | USD 35 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Initiative to rationalize operations and provide expense efficiencies. Expected to include elimination of approximately 2% to 3% of workforce. $34.9 million pre-tax recorded in FY2015. Completion extended to first half of FY2016. | |
| 2015-12-26 | restructuring | in_progress | USD 34,931,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2015-12-26 | restructuring | in_progress | Employee Severance | USD 26,742,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-12-26 | restructuring | in_progress | Facility Closing | USD 5,706,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-12-26 | restructuring | in_progress | Other Restructuring | USD 2,483,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-12-26 | restructuring | in_progress | Healthcare Distribution | USD 33,889,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-12-26 | restructuring | in_progress | Technology | USD 1,042,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-09-26 | restructuring | in_progress | 2014-11-06 | 2016-06-30 | Global | Corporate-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program involves eliminating approximately 2% to 3% of workforce plus certain facility closures; no absolute headcount given. Total expected pre-tax costs $35M–$40M, of which $30M–$35M in fiscal 2015; $8.4M recorded in Q3 and $22.5M in nine months. Completion slipped from end of fiscal 2015 to first half of fiscal 2016. Per 2015-10-29 estimate, remaining costs $12M–$15M ($6M–$7M severance, $6M–$8M facility). | |||
| 2015-09-26 | acquisition_addition | completed | 2015-09-01 | Denmark, Norway, Sweden | Health care distribution — animal health | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of an 85% interest in Jorgen Kruuse A/S completed and announced 2015-09-01; headcount added not disclosed. KRUUSE had 2014 sales of approximately $90 million. Other nine-month acquisitions were immaterial individually and in aggregate. | ||||
| 2015-09-26 | restructuring | in_progress | 2.5% | 2014-11-06 | 2016-06-30 | Global | Corporate and Operating Segments | USD 23 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014 to rationalize operations. Expected to eliminate 2-3% of workforce. Completion extended to first half of fiscal 2016. $22.5M recorded in 9 months ended Sept 26, 2015. | |
| 2015-09-26 | restructuring | in_progress | USD 8,438,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2015-09-26 | restructuring | in_progress | Employee Severance | USD 17,366,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-09-26 | restructuring | in_progress | Facility Closing | USD 3,611,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-09-26 | restructuring | in_progress | Other Restructuring | USD 1,545,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-09-26 | restructuring | in_progress | Healthcare Distribution | USD 21,506,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-09-26 | restructuring | in_progress | Technology | USD 1,016,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-06-27 | restructuring | in_progress | 2014-11-06 | 2015-12-26 | Global | Company-wide (operations rationalization) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Initiative announced 2014-11-06 to eliminate approximately 2% to 3% of workforce and close certain facilities; no absolute headcount disclosed. Total expected pre-tax costs are a range of $35 million to $40 million (about $0.29 to $0.33 per diluted share); $7.2 million recorded in Q2 2015 and $14.1 million in the six months ended 2015-06-27. Per a 2015-07-28 update, remaining expected costs of $23 million to $28 million consist of $12-14M severance and benefits, $9-11M facility costs, and $2-3M other. Accrued restructuring balance was $6.97 million at 2015-06-27. | |||
| 2015-06-27 | acquisition_addition | announced | 2015-06-23 | 2015-09-30 | Denmark, Norway and Sweden | Animal health distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement announced 2015-06-23 to acquire an 85% interest in Jorgen Kruuse A/S, a veterinary supplies distributor with 2014 sales of approximately $90 million; expected to close in Q3 2015. No headcount disclosed. | |||
| 2015-06-27 | acquisition_addition | completed | 2015-07-10 | Romania | Animal health distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 50% ownership investment in Maravet S.A., a privately held Romanian animal health distributor with annual sales of approximately $23 million, made during the quarter ended 2015-06-27 and announced 2015-07-10. No headcount disclosed. | ||||
| 2015-06-27 | acquisition_addition | completed | Europe | Animal health | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of an animal health business in Europe completed during the quarter ended 2015-06-27, with approximate aggregate annual revenues of $64.0 million; cited as a driver of a material change in internal control over financial reporting. No headcount disclosed. | |||||
| 2015-06-27 | restructuring | in_progress | 2.5% | 2014-11-06 | 2015-12-26 | Global | Corporate and Operating Segments | USD 14 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 2014 to rationalize operations. Expected to eliminate 2-3% of workforce. $14.1M recorded in first six months of 2015. Total expected cost $35-40M pre-tax. | |
| 2015-06-27 | restructuring | in_progress | USD 7,222,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2015-06-27 | restructuring | in_progress | Employee Severance | USD 11,227,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-06-27 | restructuring | in_progress | Facility Closing | USD 1,753,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-06-27 | restructuring | in_progress | Other Restructuring | USD 1,104,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-06-27 | restructuring | in_progress | Healthcare Distribution | USD 13,104,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-06-27 | restructuring | in_progress | Technology | USD 980,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-03-28 | restructuring | in_progress | 2014-11-06 | 2015-12-26 | Global | Corporate-wide (health care distribution and technology/value-added services) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program announced 2014-11-06 to rationalize operations during fiscal 2015; expected to eliminate approximately 2% to 3% of workforce and close certain facilities (no absolute headcount disclosed). Total expected pre-tax cost of $35 million to $40 million ($0.29 to $0.33 per diluted share); $6.9 million recorded in Q1 2015. As of 2015-04-30, remaining expected costs of $30 million to $35 million ($18-20M severance, $10-12M facility, $2-3M other). Accrued restructuring balance at 2015-03-28 was $4.8 million. | |||
| 2015-03-28 | acquisition_addition | completed | 2015-03-31 | 2015-03-31 | North America and Europe | Animal health (health care distribution) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of scil animal care company GmbH, a specialty distributor of animal health laboratory and imaging diagnostic products, completed 2015-03-31 (after quarter end). Annual sales of approximately $83 million; no employee headcount disclosed. | |||
| 2015-03-28 | acquisition_addition | completed | Europe | Dental (health care distribution) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Two dental businesses in Europe acquired during the quarter ended 2015-03-28 with approximate aggregate annual revenues of $15.0 million; no employee headcount disclosed. Filer also notes prior-year acquisitions (~$409.0 million aggregate annual revenues) undergoing integration and a new warehouse management system implementation for the Australia animal health business (~$35.0 million annual revenues), together deemed a material change in internal control over financial reporting. | |||||
| 2015-03-28 | restructuring | in_progress | 2.5% | 2014-11-06 | 2015-12-31 | Global | Corporate / All Segments | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiative announced Nov 6, 2014 to rationalize operations. Expected to eliminate 2-3% of workforce and close facilities. Total expected cost $35-40M. $6.9M recorded in Q1 2015. Remaining expected cost $30-35M. | |
| 2015-03-28 | restructuring | in_progress | USD 6,862,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2015-03-28 | restructuring | in_progress | Employee Severance | USD 5,086,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-03-28 | restructuring | in_progress | Facility Closing | USD 886,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-03-28 | restructuring | in_progress | Other Restructuring | USD 890,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-03-28 | restructuring | in_progress | Healthcare Distribution | USD 6,860,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-03-28 | restructuring | in_progress | Technology | USD 2,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-12-27 | restructuring | announced | 2014-11-06 | 2015 | Not specified; corporate-wide initiative | Not specified; corporate initiative across operations | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Announced November 6, 2014: initiative to rationalize operations and deliver expense efficiencies, including closure of certain facilities, with actions to occur throughout fiscal 2015. Expected to eliminate approximately 2% to 3% of the workforce (no absolute headcount disclosed; 2-3% of >17,500 employees implies roughly 350-530 positions, not stated by filer). Expected pre-tax costs of $35 million to $40 million (approximately $0.29 to $0.33 per diluted share); cost types not yet determined at year-end. Also disclosed in Item 7 MD&A (Plans of Restructuring). Status at fiscal year-end 2014: announced, execution pending in fiscal 2015. A separate, completed 2012 restructuring program (~200 positions, ~$15.2 million) had no current-year activity and is excluded per multi-year program rule. | |||
| 2014-12-27 | restructuring | announced | 2014-11-06 | 2015-12-31 | Global | Corporate / multiple | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program to rationalize operations and provide expense efficiencies throughout fiscal 2015; expected to eliminate approximately 2% to 3% of workforce and close certain facilities, with pre-tax costs of $35 million to $40 million (approximately $0.29 to $0.33 per diluted share). No employees-affected count or charge amount stated as a single figure; no provision recorded in fiscal 2014. | |||
| 2014-12-27 | acquisition_addition | completed | 2014-02-03 | 2014-02-03 | France, Netherlands, Belgium | Health care distribution; technology and value-added services | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 100% of five businesses from Arseus NV with annual sales of approximately $97 million; headcount added not disclosed | |||
| 2014-12-27 | acquisition_addition | completed | 2014-04-02 | 2014-04-02 | Poland | Animal health | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 80% of Medivet S.A. with annual sales of approximately $80 million; headcount added not disclosed | |||
| 2014-12-27 | acquisition_addition | completed | 2014-06-30 | 2014-06-30 | United States | Animal health | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 60% of SmartPak Equine, LLC, which had sales of approximately $105 million in 2013; headcount added not disclosed | |||
| 2014-12-27 | acquisition_addition | in_progress | 2014-11-20 | 2015-06-30 | United States | Medical | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Long-term strategic agreement with Cardinal Health to acquire its physician office-focused commercial organization with annual sales of more than $300 million; integration expected during the second quarter of 2015; headcount added not disclosed | |||
| 2014-12-27 | restructuring | announced | 2.5% | 2014-11-06 | 2015-12-27 | Global | Corporate | USD 38 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Announced Nov 6, 2014. Expected to eliminate 2% to 3% of workforce (midpoint 2.5%) and close certain facilities. Costs expected $35M-$40M pre-tax (midpoint $37.5M). To occur throughout fiscal 2015. | |
| 2014-12-27 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2014-12-27 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-12-27 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-12-27 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-12-27 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-09-27 | restructuring | announced | 2014-10-31 | Global | Corporate / enterprise-wide | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter decision (Oct 31, 2014) on a corporate initiative to rationalize operations; eliminates approximately 2% to 3% of workforce and closes certain facilities during fiscal 2015. Expected pre-tax cost disclosed as a range of $35 million to $40 million (about $0.29 to $0.33 per diluted share); cost breakdown by type not yet determinable. Also disclosed in Item 5 — Other Information (deduplicated). | ||||
| 2014-09-27 | acquisition_addition | completed | North America | Dental and Animal Health | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Dental and Animal Health businesses completed during the quarter ended September 27, 2014, with approximate aggregate annual revenues of $114.0 million; no headcount added was disclosed | |||||
| 2014-09-27 | restructuring | announced | 2.5% | 2014-10-31 | 2015-12-31 | Global | Corporate | USD 38 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Announced Oct 31, 2014. Expected to eliminate 2% to 3% of workforce and close certain facilities. Costs expected to be $35 million to $40 million pre-tax. Occurring throughout fiscal 2015. | |
| 2014-09-27 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2014-09-27 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-09-27 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-09-27 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-09-27 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-06-28 | acquisition_addition | completed | 2014-04-02 | 2014-04-02 | Poland | Animal health distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Medivet is a privately held animal health distributor with annual sales of approximately $80 million; headcount added not disclosed. | |||
| 2014-06-28 | acquisition_addition | completed | 2014-05-22 | 2014-06-30 | United States | Animal health distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Transaction completed June 30, 2014, after the June 28, 2014 quarter end; SmartPak had sales of approximately $105 million in 2013; headcount added not disclosed. | |||
| 2014-06-28 | restructuring | completed | 200 | 2012-12-29 | Global | Health Care Distribution | USD 15 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program initiated in FY2012 involving elimination of approx. 200 positions. Program is complete; no additional costs expected. Remaining accrual of $0.548M as of June 28, 2014. | ||
| 2014-06-28 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2014-06-28 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-06-28 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-06-28 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-06-28 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-03-29 | acquisition_addition | completed | 2014-01-06 | 2014-02-03 | France, Netherlands, Belgium | Health care distribution; Technology and value-added services | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of five businesses from Arseus NV (combined annual sales ~$97 million), completed February 3, 2014; no headcount disclosed. | |||
| 2014-03-29 | acquisition_addition | completed | 2013-11-14 | 2014-04-02 | Poland | Health care distribution (animal health) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 80% acquisition of Medivet S.A. (annual sales ~$80 million) completed April 2, 2014, after quarter end; no headcount disclosed. | |||
| 2014-03-29 | restructuring | completed | 200 | 2012-12-29 | 2014-03-29 | Global | Health Care Distribution | USD 15 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program initiated in FY2012 involving elimination of approx. 200 positions. Filer states program is complete and no additional costs are expected. Remaining accrued balance of $0.661 million as of period end. | |
| 2014-03-29 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2014-03-29 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-03-29 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-03-29 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-03-29 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-12-28 | divestiture_reduction | completed | 2013-07-10 | 2013-07-10 | Middle East | Dental wholesale distribution | USD 13 (millions) | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Divestiture of an equity investment in a dental wholesale distributor; $12.5M one-time loss recognized. No headcount associated with the divestiture was disclosed. | ||
| 2013-12-28 | acquisition_addition | completed | 2013-12-30 | United States | Dental implants manufacturing | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of an approximately 60% equity investment in BioHorizons, Inc., completed one day after fiscal year-end; target annual revenues approximately $115 million. No headcount disclosed. | ||||
| 2013-12-28 | acquisition_addition | announced | 2014-01-06 | 2014-03-31 | France, Netherlands, Belgium | Dental product distribution and practice management software | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Announced acquisition of five businesses from Arseus NV with combined annual sales of approximately $97 million; completed during Q1 2014. No headcount disclosed. | |||
| 2013-12-28 | restructuring | completed | 200 | 2012-12-30 | 2013-12-28 | Global | Various | USD 15 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Program initiated in FY2012 involving elimination of approximately 200 positions. Costs included severance, facility closing, and professional fees. Program completed with no additional costs expected in FY2013. | |
| 2013-12-28 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2013-12-28 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-12-28 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-12-28 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-12-28 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-09-28 | restructuring | completed | 200 | 2012-01-01 | 2013-09-28 | Global | Corporate and Operating Segments | USD 15,192 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program initiated in FY2012 involving elimination of approx. 200 positions. Filer states program is complete as of Q3 2013. | |
| 2013-09-28 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2013-09-28 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-09-28 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-09-28 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-09-28 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-06-29 | divestiture_reduction | announced | 2013-07-10 | Middle East | Health care distribution (dental wholesale) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Divestiture of an investment in a Middle East dental wholesale distributor; expected one-time loss of $11-13 million ($0.13-0.15 per diluted share) in Q3 2013. No headcount impact disclosed. | ||||
| 2013-06-29 | restructuring | completed | 2012-01-01 | USD 0 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program initiated in 2012 involving elimination of approx. 200 positions. No new provisions recorded in current quarter; program is complete. | |||||
| 2013-06-29 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2013-06-29 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-06-29 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-06-29 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-06-29 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-03-30 | restructuring | completed | USD 0 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Filer states restructuring programs are complete and no additional costs are expected. No new provision was recorded in Q1 2013; payments of $1.5 million were made against prior accruals. | ||||||
| 2013-03-30 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2013-03-30 | restructuring | in_progress | Employee Severance | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-03-30 | restructuring | in_progress | Facility Closing | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-03-30 | restructuring | in_progress | Technology | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-03-30 | restructuring | in_progress | Healthcare Distribution | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-12-29 | restructuring | completed | 200 | Primarily Health Care Distribution segment | USD 15 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Approximately 200 positions eliminated. Charge of ~$15.2M (~$10.5M after tax) comprised of severance of ~$12.8M, facility closing costs of ~$2.4M, and outside professional fees; costs incurred in Q1 fiscal 2012 (per Note 18). Provision by segment: ~$15.0M health care distribution, ~$0.2M technology and value-added services. Program stated as complete with majority of costs payable in 2013. | ||||
| 2012-12-29 | restructuring | completed | 200 | 2012-12-29 | Not specified | Not specified | USD 15 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2012 program: approximately 200 positions eliminated via severance pay and benefits, plus facility closing costs (lease terminations and asset write-offs) and consulting fees. Filer states the program is complete with no additional costs expected; majority of costs to be paid in 2013. Charge of $15.2M pre-tax ($10.5M after tax). | ||
| 2012-12-29 | acquisition_addition | completed | 2012-12-29 | Not specified | Global dental and animal health | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | During Q4 2012 the company completed acquisitions of global dental and animal health businesses with approximate aggregate annual revenues of $83.0M and $57.0M respectively. Headcount added through these acquisitions was not disclosed. | ||||
| 2012-12-29 | acquisition_addition | in_progress | Not specified | Global animal health, dental, medical and technology | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Post-acquisition integration activities continued through Q4 2012 for businesses acquired during 2012 and 2011 with aggregate annual revenues of approximately $674.0M; most use separate information and accounting systems. Headcount added was not disclosed. | |||||
| 2012-12-29 | restructuring | completed | 200 | 2012-01-01 | 2012-12-29 | Global | Various | USD 15 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Elimination of approximately 200 positions. Program complete. Majority of costs expected to be paid in 2013. | |
| 2012-12-29 | restructuring | in_progress | 200 | USD 15,192,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-12-29 | restructuring | in_progress | Employee Severance | USD 12,841,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-12-29 | restructuring | in_progress | Facility Closing | USD 2,351,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-12-29 | restructuring | in_progress | Healthcare Distribution | USD 14,981,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-12-29 | restructuring | in_progress | Technology | USD 211,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-09-29 | restructuring | completed | 200 | USD 15 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approximately 200 positions eliminated during the nine months ended September 29, 2012; charge of $15.2M ($10.5M after taxes) covering severance, facility closings and consulting fees. Program reported as complete with no further costs expected in fiscal 2012. Announcement date not disclosed. | |||||
| 2012-09-29 | acquisition_addition | completed | Medical, technology and dental businesses | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisitions completed during the quarter ended September 29, 2012 with approximate aggregate annual revenues of $102.0 million; headcount added not disclosed. Ongoing integration of prior acquisitions representing aggregate annual revenues of approximately $643.0 million also cited as a material change in internal control over financial reporting. | ||||||
| 2012-09-29 | restructuring | completed | 200 | USD 15 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program complete for the nine months ended Sept 29, 2012. Costs include severance, facility closing, and professional fees. | |||||
| 2012-09-29 | restructuring | in_progress | 200 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-09-29 | restructuring | in_progress | Employee Severance | USD 12,841,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-09-29 | restructuring | in_progress | Facility Closing | USD 2,351,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-09-29 | restructuring | in_progress | Healthcare Distribution | USD 14,981,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-09-29 | restructuring | in_progress | Technology | USD 211,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-06-30 | restructuring | completed | 200 | 2012-06-30 | Not specified | Not specified | USD 15 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approximately 200 positions eliminated during the six months ended June 30, 2012; severance and benefits plus facility closing costs and consulting fees. Filer states the program is complete with no further costs expected in fiscal 2012. $10.5 million after taxes. No announcement date disclosed. | ||
| 2012-06-30 | acquisition_addition | completed | 2012-06-30 | Not specified | Animal health, technology, dental | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | During Q2 2012 the company completed acquisitions of an animal health business, a technology business and three dental businesses with approximate aggregate annual revenues of $334.0 million; headcount added not disclosed. Post-acquisition integration continued for two animal health businesses (approx. $309.0 million aggregate annual revenues) acquired in 2011 and Q1 2012. | ||||
| 2012-06-30 | restructuring | completed | 200 | 2012-12-29 | USD 15 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Program involves elimination of approximately 200 positions, facility closing costs, and professional fees. Filer states program is complete and no additional costs expected for remainder of fiscal year. | ||||
| 2012-06-30 | restructuring | in_progress | 200 | USD 3,360,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2012-03-31 | restructuring | in_progress | 150 | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Elimination of approximately 150 positions plus facility closings and consulting fees; $11.8M pre-tax ($8.3M after tax). Additional charges of $2M–$4M ($0.02–$0.03 per diluted share) expected in Q2 2012, so program remains in progress. Restructuring costs reported by segment (Health Care Distribution $11,775K; Technology $57K) but headcount not split by segment. | |||||
| 2012-03-31 | acquisition_addition | announced | 2012-04-11 | 2012-06-30 | Netherlands | Animal Health | USD 38 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement to acquire AUV Veterinary Services B.V. for approximately $38 million (purchase price, not a charge); 2011 net sales of approximately $270.4 million. Headcount added not disclosed; pending regulatory approval, expected to close Q2 2012. | ||
| 2012-03-31 | restructuring | in_progress | 150 | 2012-03-31 | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Elimination of approximately 150 positions, facility closing costs, and professional fees. Additional charges of $2-4 million expected in Q2 2012. | ||||
| 2012-03-31 | restructuring | in_progress | 150 | USD 11,832,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2011-12-31 | acquisition_addition | completed | 2010-12-31 | 2010-12-31 | Australia and New Zealand (Australasia) | Animal health | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired 100% of Provet Holdings Limited for approximately $91 million in a cash-for-stock exchange; the acquisition date falls within the 53-week fiscal 2011 (MD&A describes it as occurring at the beginning of fiscal 2011). Added employee headcount not disclosed; target had approximately $278 million of fiscal 2010 sales. | |||
| 2011-12-31 | restructuring | announced | 2012-02-15 | 2012-12-31 | USD 11 (millions) | MD&A f5-10k / GLM-5.3-flash-HTML | Restructuring to be implemented during 2012 with the goal of improving profitability; charges expected of approximately $11 million to $13 million (about $0.08 to $0.10 per diluted share) during the first half of 2012 — the value field reflects the low end of the disclosed range. Employee count not disclosed. announcement_date is the 10-K filing/certification date; no subsequent-events footnote identifies an earlier announcement date. No restructuring provision was recorded in fiscal 2011 for prior (2008 and 2010) programs, which involved headcount actions in prior fiscal years and are therefore not captured here. | ||||
| 2011-12-31 | restructuring | announced | 2012-06-30 | USD 11 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Company states it will implement a restructuring during 2012 to improve profitability, with expected charges of $11 million to $13 million (approximately $0.08 to $0.10 per diluted share) recorded in the first half of 2012; no headcount target disclosed. Announcement date not stated in the filing. | |||||
| 2011-12-31 | acquisition_addition | completed | 2011-12-30 | 2011-12-30 | United States | Animal health (Healthcare Distribution) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquired all remaining Oak Hill Capital Partners direct and indirect interests in Butler Animal Health Supply for $155 million cash, raising ownership to approximately 71.7%; headcount added through the transaction not disclosed. | |||
| 2011-12-31 | restructuring | completed | 430 | 2008-11-05 | Global | Operations | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Announced in 2008, elimination of approximately 430 positions and closing of several smaller facilities. Costs incurred in 2009 and 2010. | |||
| 2011-12-31 | restructuring | completed | 184 | 2010-03-31 | Global | Operations | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Completed in first quarter of 2010. Headcount reductions of 184 positions and closing of a number of smaller locations. | |||
| 2011-12-31 | restructuring | announced | 2011-12-31 | 2012-06-30 | Global | Operations | USD 12 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Announced for implementation in 2012. Expected charges of $11 million to $13 million in first half of 2012. Employee count not disclosed. | ||
| 2011-12-31 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2011-09-24 | restructuring | completed | 184 | 2010-03-31 | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program completed in Q1 2010 (headcount reductions of 184 positions plus closure of smaller locations); the $12.3M charge relates to the prior-year nine-month period, not the current quarter. Current filing discloses only the accrual roll-forward: $4.3M balance at 2010-12-25, $3.0M paid/adjusted during the nine months, $1.3M remaining at 2011-09-24, all in Healthcare distribution. No new workforce actions were disclosed for the quarter ended 2011-09-24. | ||||
| 2011-09-24 | restructuring | completed | 184 | 2010-01-01 | 2010-03-31 | United States | Healthcare distribution | USD 12,285 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed in Q1 2010. Included headcount reductions of 184 positions and closing of smaller locations. Total costs approx $12.3 million. | |
| 2011-09-24 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2011-06-25 | restructuring | completed | 184 | 2010-01-01 | United States | Healthcare distribution | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring completed in Q1 2010 involving headcount reductions of 184 positions and closing of smaller locations. Costs recorded in prior year. | ||
| 2011-06-25 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2011-03-26 | restructuring | completed | 184 | 2010-01-01 | 2010-03-27 | United States | Healthcare distribution | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Restructuring completed in Q1 2010 included headcount reductions of 184 positions and closing of smaller locations. Costs included severance, facility closing, and professional fees. | |
| 2011-03-26 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2010-12-25 | restructuring | completed | 184 | 2010 | 2010 | Primarily healthcare distribution segment | USD 12 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Headcount reduction of 184 positions plus closure of a number of smaller locations, executed during the first quarter of fiscal 2010 (no explicit announcement date disclosed). FY2010 restructuring costs of approximately $12.3 million pre-tax (about $8.3 million after tax): severance $8.8 million, facility closing $3.4 million, other professional and consulting $0.1 million. Charge allocated $12.1 million to healthcare distribution and $0.2 million to technology; $4.3 million accrual remained at fiscal year-end. A separate prior program announced November 5, 2008 (approximately 430 positions) is re-disclosed but its headcount activity was recorded in fiscal 2008 and is excluded per current-year-only rule. | ||
| 2010-12-25 | restructuring | completed | 184 | 2010-03-31 | Not specified | Company-wide | USD 12 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Completed during the first quarter of 2010: headcount reduction of 184 positions plus closure of several smaller locations. FY2010 charge of $12.3M comprises severance $8.8M, facility closing $3.4M and other professional/consulting $0.1M (approximately $8.3M after taxes). Announcement date not disclosed. | ||
| 2010-12-25 | acquisition_addition | completed | 2009-12-31 | 2009-12-31 | United States | Animal health | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Effective December 31, 2009 (within FY2010, which began December 27, 2009). Total consideration $351.1M including $96.1M for noncontrolling interests; 50.1% of Butler Holding acquired for approximately $42.0M cash plus contribution of the U.S. animal health business. Headcount added not disclosed; drove 270.4% animal health sales growth in FY2010. | |||
| 2010-12-25 | acquisition_addition | completed | Not specified | Not specified | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Additional acquisitions completed during FY2010 were immaterial individually and in the aggregate, resulting in approximately $162.9M of initial goodwill. Headcount added not disclosed. | |||||
| 2010-12-25 | acquisition_addition | announced | 2010-10-14 | Australia | Animal health | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Agreement announced October 14, 2010 to acquire 100% of Provet Holdings Limited (ASX: PVT) for approximately $91 million in a cash-for-stock exchange; closed after fiscal year-end. Headcount not disclosed. | ||||
| 2010-12-25 | restructuring | completed | 184 | 2010-01-01 | 2010-03-31 | Global | Various | USD 12 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Completed in first quarter of 2010. Included headcount reductions of 184 positions and closing of smaller locations. Total restructuring costs recorded were $12.3 million. | |
| 2010-12-25 | acquisition_addition | completed | 2009-12-31 | 2009-12-31 | United States | Animal Health | business_combinations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Acquired majority interest in Butler Animal Health Supply, LLC effective December 31, 2009. Employee count not explicitly disclosed in filing. | |||
| 2010-12-25 | restructuring | in_progress | USD 12,285,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2010-09-25 | restructuring | in_progress | 430 | 2008-11-05 | Not specified | Operations | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program announced November 5, 2008 eliminated approximately 430 positions and closed several smaller facilities; a severance/facility accrual of $4.3 million remained at December 26, 2009, indicating the program was not fully wound down. | |||
| 2010-09-25 | restructuring | completed | 184 | 2010-03-27 | Not specified | Not specified | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Additional restructuring completed in the first quarter of fiscal 2010 (headcount reductions of 184 positions plus closure of smaller locations). Charge of approximately $12.3 million ($8.3 million after taxes) is the nine-month provision covering severance, facility closing and consulting costs; no separate announcement date is disclosed. | ||
| 2010-09-25 | acquisition_addition | completed | 2009-12-31 | United States | Animal health (Healthcare distribution) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Majority interest in Butler Animal Health Supply, LLC acquired effective December 31, 2009; acquired headcount is not disclosed. Butler Schein Animal Health had $320.0 million of debt at closing. | ||||
| 2010-09-25 | acquisition_addition | announced | 2010-10-14 | 2010-12-31 | Australia | Animal health (Healthcare distribution) | USD 91 (millions) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter announcement (October 14, 2010) to acquire 100% of Provet Holdings Limited for approximately $91 million in a cash-for-stock exchange, subject to shareholder and court approval; expected to close at or around year end. Headcount added not disclosed. | ||
| 2010-09-25 | acquisition_addition | completed | 2010-09-25 | North America and international | Dental and Animal Health | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Dental and Animal Health businesses with approximate aggregate annual revenues of $17.0 million acquired during the quarter; headcount added not disclosed. Related integrations covered businesses representing aggregate annual revenues of approximately $880.0 million. | ||||
| 2010-09-25 | restructuring | completed | 184 | 2010-01-01 | United States | Healthcare distribution and Technology | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed in Q1 2010. Included headcount reductions of 184 positions and closing of smaller locations. Total charge $12.3M for nine months ended Sept 25, 2010. | ||
| 2010-09-25 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2010-06-26 | restructuring | completed | 184 | 2010-03-27 | Not specified | Not specified | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Completed during Q1 2010: 184 positions eliminated plus closure of several smaller locations. $12.3M charge is the full six-month 2010 provision (severance, facility closures, consulting fees); exact announcement date not disclosed. A prior program announced 2008-11-05 eliminated approximately 430 positions. | ||
| 2010-06-26 | acquisition_addition | completed | 2010-06-26 | North America | Dental (Healthcare distribution) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | North American dental business acquired during the quarter with approximate annual revenues of $121.0 million; headcount added not disclosed. Acquisition costs were immaterial per Note 4. | ||||
| 2010-06-26 | acquisition_addition | completed | 2009-12-31 | 2009-12-31 | North America | Animal health (Healthcare distribution) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Majority interest in Butler Animal Health Supply acquired effective 2009-12-31 (annual revenues ~$840.0 million); post-acquisition integration continued through the quarter. Headcount added not disclosed. | |||
| 2010-06-26 | restructuring | completed | 184 | 2010-01-01 | 2010-03-31 | United States | Healthcare distribution and Technology | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed in Q1 2010. Included headcount reductions of 184 positions and closing of smaller locations. Total provision for six months ended June 26, 2010 was $12.3 million. | |
| 2010-06-26 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2010-03-27 | restructuring | completed | 184 | 2010-03-27 | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Completed during Q1 2010: 184 positions eliminated plus closure of several smaller locations. Charge comprises severance $8.8M, facility closing $3.4M, consulting $0.1M; accrued balance $13.1M at quarter end, majority expected to be paid in 2010. Separate prior program announced 2008-11-05 eliminated ~430 positions and remains open with accruals. No announcement date or geography disclosed for the Q1 2010 action. | ||||
| 2010-03-27 | restructuring | in_progress | 184 | 2010-01-01 | 2010-12-31 | Global | Healthcare distribution and Technology | USD 12 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed additional restructuring in Q1 2010 including headcount reductions of 184 positions and closing of smaller locations. Majority of costs expected to be paid in 2010. | |
| 2009-12-26 | restructuring | completed | 430 | 2008-11-05 | Global operations | Primarily healthcare distribution segment | USD 3 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Program announced November 5, 2008: elimination of approximately 430 positions and closure of several smaller facilities. FY2009 provision was $3.0 million pretax (severance ~$1.5 million; facility closing ~$1.5 million); the FY2008 provision was $23.2 million. Majority of cumulative costs paid as of December 26, 2009; annual pretax savings expected of $24-27 million. Note 17 (quarterly data) cites approximately 300 positions (~2.5% of workforce), inconsistent with the 430 figure in Note 8 and MD&A; the restructuring footnote figure is used. The Q1 2010 restructuring below is described as additional to this program. | ||
| 2009-12-26 | restructuring | announced | 2010-02-23 | 2010-03-31 | Primarily European operations | International operations | USD 10 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Additional restructuring comprising headcount reductions and facility closings, part of a plan to increase international operating margins; disclosed in the FY2009 Form 10-K (filed February 23, 2010). Expected costs of $10-12 million pretax ($7-9 million after taxes), expected to be reported in Q1 2010, though timing of certain actions may push some costs later; no employee count disclosed. | ||
| 2009-12-26 | acquisition_addition | completed | 2009-12-31 | United States | Animal health | subsequent_events f5-10k / GLM-5.3-flash-HTML | Effective December 31, 2009, acquired a majority interest (50.1%) in Butler Animal Health Supply, LLC jointly with Oak Hill Capital Partners; contributed the US animal health business (net book value ~$91.6 million) plus ~$43.5 million cash, and BAHS incurred ~$320.0 million of debt reflected on the consolidated balance sheet. Employee headcount added was not disclosed. | ||||
| 2009-12-26 | divestiture_reduction | completed | 2009-08-05 | Dental (healthcare distribution) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Completed sale of a wholesaler of dental consumables for aggregate consideration of $14.2 million; business presented as discontinued operations (net gain of $2.6 million after tax in 2009). No employee headcount disclosed for the divested business. | |||||
| 2009-12-26 | restructuring | in_progress | 430 | 2008-11-05 | Global | Operations (incl. closure of several smaller facilities) | USD 3 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 430 positions is the cumulative program total announced 2008-11-05; the FY2009-attributable portion of separations is not separately disclosed. Charge shown is the FY2009 provision ($3.0M pretax / ~$2.1M after tax); FY2008 provision was $23.2M. Annual pretax cost savings of $24-27M expected. A separate quarterly footnote cites 'approximately 300 positions' for the same program. | ||
| 2009-12-26 | restructuring | announced | 2010-03-31 | Europe | International operations (headcount reductions and facility closings) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Expected charge of $10-12 million pretax ($7-9 million after taxes), reported as a range so no single value extracted; timing of some actions may push costs into later periods. Part of the plan to increase international operating margins. | ||||
| 2009-12-26 | acquisition_addition | completed | 2009-11-29 | 2009-12-31 | United States | Healthcare Distribution — Animal Health | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Majority interest (50.1%) in Butler Animal Health Supply, LLC acquired effective 2009-12-31, one day after fiscal year-end; $43.5M cash plus contribution of US animal health assets with ~$91.6M net book value, and ~$320.0M of debt incurred at the JV. No employee headcount for the acquired business is disclosed. | |||
| 2009-12-26 | divestiture_reduction | completed | 2009-08-05 | Healthcare Distribution — dental consumables wholesale | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of a dental consumables wholesaler completed 2009-08-05 for $14.2M aggregate consideration; business reported as discontinued operations. No headcount associated with the disposition is disclosed. | |||||
| 2009-12-26 | restructuring | completed | 430 | 2008-11-05 | 2009-12-26 | Global | Operations | USD 3 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Announced Nov 2008. Elimination of 430 positions and closing of several smaller facilities. $3.0M recorded in FY2009 (remainder in FY2008). Majority of costs paid as of Dec 26, 2009. | |
| 2009-12-26 | restructuring | announced | 2009-12-26 | 2010-03-31 | Europe | International Operations | USD 11 (millions) | subsequent_events f5-10k / Qwen3.6-27B-Q8_0 | Expected to complete in Q1 2010. Includes headcount reductions and facility closures. Estimated cost $10M-$12M. | ||
| 2009-09-26 | restructuring | in_progress | 430 | 2008-11-05 | 2009-12-31 | Not specified | Not specified | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program eliminated 430 positions and closed several smaller facilities; $4.0M charge recorded in nine months ended 2009-09-26 ($2.8M after tax), $6.979M accrual remaining at quarter-end; annual pretax cost savings expected of $24-27M; majority of remaining costs expected to be paid in 2009 | |
| 2009-09-26 | divestiture_reduction | completed | 2009-08-05 | 2009-08-05 | Not specified | Healthcare distribution — dental consumables wholesale | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of dental consumables wholesaler completed 2009-08-05 for $14.2M aggregate consideration; associated headcount not disclosed | |||
| 2009-09-26 | restructuring | in_progress | 430 | 2008-11-05 | Global | Operations | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Announced Nov 5, 2008. Elimination of 430 positions and closing of several smaller facilities. $4.0M recorded for nine months ended Sept 26, 2009. | ||
| 2009-06-27 | restructuring | in_progress | 430 | 2008-11-05 | Healthcare distribution and Technology | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 430 positions eliminated cumulatively since the November 5, 2008 announcement (not a quarterly figure), plus closure of several smaller facilities. $4.0M charged in six months ended June 27, 2009 ($2.8M after tax), all in healthcare distribution segment; remaining accrual $10.5M at quarter end. Majority of costs expected paid during 2009; annual pretax savings of $24M-$27M expected. | |||
| 2009-06-27 | acquisition_addition | completed | Canada and Israel | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Two acquisitions completed during the quarter with aggregate annual revenues of $28.0 million (per Item 4); described as immaterial individually and in aggregate. No headcount added disclosed. | ||||||
| 2009-06-27 | restructuring | in_progress | 430 | 2008-11-05 | 2009-12-31 | Global | Healthcare Distribution and Technology | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Announced Nov 5, 2008. Elimination of 430 positions and closing of several smaller facilities. $4.0M recorded in first half of 2009. Majority of costs expected to be paid in 2009. | |
| 2009-03-28 | restructuring | in_progress | 400 | 2008-11-05 | 2009-12-31 | Not specified | Healthcare distribution (Q1 2009 provision recorded entirely in this segment) | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program eliminated approximately 400 positions and closed several smaller facilities; $4.0M provision recorded in Q1 2009 ($2.8M after tax), $15.9M accrued balance remaining at quarter end, majority of costs expected to be paid in 2009; annual pretax cost savings of $24.0M-$27.0M expected. | |
| 2009-03-28 | acquisition_addition | completed | Not specified | Not specified | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Two acquisitions completed during the quarter with aggregate annual revenues of $10.0 million; headcount added not disclosed. MD&A also references ongoing integration of businesses acquired since September 2008 with approximate aggregate annual revenues of $289.0 million. | |||||
| 2009-03-28 | restructuring | in_progress | 400 | 2008-11-05 | 2009-12-31 | Global | Operations | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Announced Nov 5, 2008. Elimination of approx 400 positions and closing of several smaller facilities. Q1 2009 provision was $4.0 million. | |
| 2008-12-27 | restructuring | in_progress | 300 | 2.5% | 2008-11-05 | Not specified (company-wide) | Healthcare distribution and technology segments (cost split disclosed; headcount not split) | USD 23 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Cost-reduction plan announced November 5, 2008: elimination of approximately 300 positions (roughly 2.5% of the workforce at that time, not at fiscal year-end) together with closure of several smaller facilities (primarily certain equipment branches). Fiscal 2008 one-time charge of $23.2 million pre-tax ($16.0 million after tax), comprising $18.6 million severance pay and benefits, $3.8 million facility closing costs (primarily lease terminations and asset write-offs) and $0.8 million professional/consulting fees; by segment, $22.65 million healthcare distribution and $0.59 million technology. $4.7 million paid in 2008, leaving an $18.5 million accrual at fiscal year-end, with the majority expected to be paid in 2009 and $1.0–3.0 million of additional costs expected in Q1 2009. Expected annual pre-tax savings of $24.0–27.0 million. No explicit program completion date disclosed; the 300-position figure is a consolidated total and is not broken down by segment or geography. Headcount impact of the facility closures is not separately quantified. | |
| 2008-12-27 | restructuring | in_progress | 300 | 2.5% | 2008-11-05 | 2009-03-31 | Global | Operations (multiple smaller facilities) | USD 23 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program eliminated approximately 300 positions (about 2.5% of workforce) and closed several smaller facilities; $16.0M after taxes. $18.5M accrued at year-end; remaining $1.0M-$3.0M of costs expected in Q1 2009; annual pretax savings of $24.0M-$27.0M expected. |
| 2008-12-27 | acquisition_addition | completed | 2008-12-23 | 2008-12-23 | Italy, Germany, Czech Republic | Healthcare distribution (dental, medical, animal health) | USD 53 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of DNA Anthos Impianti, Medka and Noviko; aggregate purchase price ~$52.9M with combined 2008 sales of ~$165.0M. Headcount added not disclosed. | ||
| 2008-12-27 | divestiture_reduction | completed | 2008-11-30 | 2008-12-27 | United States | Healthcare distribution — wholesale ultrasound business | USD 11 (millions) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Decision reached in November 2008 to exit the wholesale ultrasound business; $11.2M impairment charge ($7.3M after-tax) including $6.7M goodwill. Headcount removed not disclosed. | ||
| 2008-12-27 | restructuring | in_progress | 300 | 2.5% | 2008-11-05 | 2009-03-31 | Global | Operations | USD 23 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Elimination of approximately 300 positions (2.5% of workforce) and closing of several smaller facilities. Majority of costs expected to be paid in 2009. Remaining costs of $1.0-$3.0 million expected in Q1 2009. |
| 2008-09-27 | restructuring | announced | 300 | 2.5% | 2008-11-05 | Worldwide | Operations | USD 25 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Expense reduction announced 2008-11-05: elimination of approximately 300 positions (about 2.5% of workforce) plus closure of several smaller facilities; one-time pretax charge disclosed as a range of $22 million to $25 million (upper bound recorded), expected to be recorded in Q4 2008. Implied workforce of ~12,000 is consistent with disclosed total headcount. | |
| 2008-09-27 | restructuring | announced | 300 | 2.5% | 2008-11-05 | Global | Operations | USD 24 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Announced elimination of approximately 300 positions (2.5% of workforce) and closing of several smaller facilities. One-time pretax charge estimated at $22 million to $25 million, expected to be recorded in Q4 2008. | |
| 2007-12-29 | acquisition_addition | completed | 2007-07-02 | 2007-07-02 | Healthcare distribution — dental | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired the 50% of Becker-Parkin Dental Supply Co. not previously owned; purchase price approximately $22 million less debt, subject to an earnout and other adjustments; annual revenues approximately $69.5 million. Acquired headcount not disclosed. | ||||
| 2007-12-29 | divestiture_reduction | completed | 2007-08-13 | 2007-08-13 | Healthcare distribution — oncology pharmaceutical | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Sold substantially all assets of the oncology pharmaceutical business for $5.9 million; previously part of the healthcare distribution segment and reported as discontinued operations. Affected headcount not disclosed. | ||||
| 2007-12-29 | acquisition_addition | completed | 2007-08-29 | 2007-08-29 | United Kingdom | Healthcare distribution — animal health | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired W&J Dunlop, Ltd., a UK supplier of animal health products and services to veterinary clinics; purchase price approximately $68.4 million including fees; annual revenues approximately $297.0 million. Acquired headcount not disclosed. | |||
| 2007-12-29 | acquisition_addition | completed | 2007-09-29 | 2007-09-29 | New Zealand | Technology — dental practice-management software | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired Software of Excellence International Ltd. for NZ$2.90 per share; total purchase price approximately $62.2 million including fees; annual revenues approximately $20.0 million. Acquired headcount not disclosed. | |||
| 2007-12-29 | divestiture_reduction | completed | 2007-12-01 | 2007-12-01 | Healthcare distribution — specialty pharmacy | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Sold substantially all assets of the specialty pharmacy business for $8.4 million; previously part of the healthcare distribution segment and reported as discontinued operations. Affected headcount not disclosed. | ||||
| 2007-12-29 | acquisition_addition | completed | 2007-09-29 | 2007-09-29 | New Zealand | Technology (dental practice management software) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Software of Excellence International Ltd. for approximately $62.2 million including fees; annual revenues approximately $20.0 million; headcount added not disclosed | |||
| 2007-12-29 | acquisition_addition | completed | 2007-08-29 | 2007-08-29 | United Kingdom | Healthcare Distribution (animal health) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of W&J Dunlop, Ltd. for approximately $68.4 million including fees; annual revenues approximately $297.0 million; headcount added not disclosed | |||
| 2007-12-29 | acquisition_addition | completed | 2007-07-02 | 2007-07-02 | United States | Healthcare Distribution (dental) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquired the 50% of Becker-Parkin Dental Supply Co. not already owned for approximately $22 million less debt and subject to earnout; annual revenues approximately $69.5 million; headcount added not disclosed | |||
| 2007-12-29 | acquisition_addition | completed | 2007-12-29 | Multiple | Multiple | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Other acquisitions completed during fiscal 2007, described as immaterial individually and in the aggregate; headcount added not disclosed | ||||
| 2007-12-29 | divestiture_reduction | completed | 2007-08-13 | 2007-08-13 | United States | Healthcare Distribution (oncology pharmaceutical business) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sold substantially all assets of oncology pharmaceutical business for $5.9 million aggregate sales price; headcount removed not disclosed | |||
| 2007-12-29 | divestiture_reduction | completed | 2007-12-01 | 2007-12-01 | United States | Healthcare Distribution (specialty pharmacy business) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sold substantially all assets of specialty pharmacy business for $8.4 million aggregate sales price; headcount removed not disclosed | |||
| 2007-09-29 | acquisition_addition | completed | United States | Healthcare distribution — Dental | USD 22 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | July 2007 purchase of the 50% of Becker-Parkin Dental Supply Co. not already owned; purchase price ~$22 million. No employee headcount disclosed; purchase price recorded as acquisition consideration, not a workforce charge. | ||||
| 2007-09-29 | acquisition_addition | completed | United Kingdom | Healthcare distribution — Medical (animal health) | USD 68 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | August 2007 acquisition of W&J Dunlop, Ltd. (supplier to UK veterinary clinics, ~$340 million annual revenues); purchase price including fees ~$68.4 million. No employee headcount disclosed. | ||||
| 2007-09-29 | acquisition_addition | completed | 2007-10-26 | New Zealand | Technology | USD 62 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Offer for Software of Excellence International Ltd. (NZX: SOE) at NZ$2.90 per share made unconditional 2007-09-29; total purchase price including fees ~$62.2 million; transaction closed 2007-10-26. A $61.6 million acquisition liability was accrued at quarter-end. No employee headcount disclosed. | |||
| 2007-09-29 | divestiture_reduction | completed | 2007-08-13 | United States | Healthcare distribution — Medical (oncology pharmaceutical business) | USD 2 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of oncology pharmaceutical business completed 2007-08-13 for $5.9 million aggregate consideration; total pretax loss on discontinued operations of $2.0 million. No employee headcount disclosed. | |||
| 2007-09-29 | divestiture_reduction | in_progress | 2007-06-30 | 2008-03-31 | United States | Healthcare distribution — Medical (specialty pharmacy) | USD 33 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision to divest lower-margin specialty pharmacy business reached in Q2 2007; sale intended within nine months of quarter-end. Includes $32.7 million ($20.6 million after-tax) impairment of long-lived assets, including $30.1 million goodwill, recorded in Q2 2007. No employee headcount disclosed. | ||
| 2007-06-30 | divestiture_reduction | announced | 2007-06-30 | 2008-06-30 | United States | Healthcare distribution — medical group (oncology pharmaceutical and specialty pharmacy businesses) | USD 33 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision reached during Q2 2007 to divest; $32.7M pre-tax impairment of long-lived assets including $30.1M goodwill; no employee count disclosed; sale expected within 12 months with an additional expected pre-tax loss of $3M–$5M | ||
| 2007-06-30 | acquisition_addition | announced | 2007-06-30 | 2007-07-31 | United States | Healthcare distribution — dental (Becker-Parkin Dental Supply Co.) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement signed June 2007 to acquire remaining 50% of Becker-Parkin for ~$22M; completed July 2007; full-service and special-markets operations to be merged into existing operations, telesales portion contributed to an unconsolidated equity investment (45% ownership); no headcount disclosed | |||
| 2007-06-30 | acquisition_addition | announced | 2007-06-30 | New Zealand | Technology segment (Software of Excellence International Ltd.) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | June 2007 announcement of intent to offer NZ$2.70 per share; total purchase price ~$58.0M expected to be paid in cash; no headcount disclosed | ||||
| 2007-03-31 | acquisition_addition | completed | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Certain acquisitions completed during the quarter; filer describes them as immaterial individually and in aggregate, and discloses no headcount added | |||||||
| 2006-12-30 | acquisition_addition | completed | 2006-03-31 | 2006-03-31 | Healthcare distribution — animal health | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired NLS Animal Health, a full-service animal health distribution business with annual revenues of approximately $110.0 million; $50.6 million of goodwill recorded. Employee headcount of acquired business not disclosed. | ||||
| 2006-12-30 | acquisition_addition | completed | 2006-06-30 | Healthcare distribution — dental and medical | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Group of acquisitions from the Darby Group: dental merchandise/equipment distributor (completed June 30, 2006), dental lab distributor and medical supplies/pharmaceutical distributor (both during Q3 2006); combined annual revenues approximately $219.0 million; $13.3 million of goodwill recorded. Employee headcount not disclosed. | |||||
| 2006-12-30 | divestiture_reduction | completed | 2006-04-01 | Healthcare distribution — Hospital Supply Business | USD 32 (millions) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Decision to divest reached in 2005 (with a $7.0 million net-of-tax long-lived asset impairment recorded in 2005); substantially all assets sold on April 1, 2006 for $36.5 million. Associated charge is the pre-tax loss on sale of $32.3 million ($19.4 million after-tax), including $3.5 million of transitional service obligations and selling costs — not a severance charge. Employee headcount of divested business not disclosed. | ||||
| 2006-12-30 | divestiture_reduction | completed | 2006-04-01 | United States | Healthcare Distribution — Hospital Supply Business | USD 32 (millions) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of substantially all Hospital Supply Business assets completed 2006-04-01 for $36.5 million; decision to divest reached in 2005 (exact announcement date not disclosed). Charge is the $32.3 million pre-tax loss on sale ($19.4 million after-tax), including $3.5 million of transitional service and selling costs. Headcount not disclosed. | |||
| 2006-12-30 | acquisition_addition | completed | 2006-03-31 | 2006-03-31 | United States | Healthcare Distribution — Animal Health | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of NLS Animal Health, a full-service animal health distributor with annual revenues of approximately $110.0 million; $50.6 million of goodwill recorded. Headcount added not disclosed. | |||
| 2006-12-30 | acquisition_addition | completed | 2006-06-30 | 2006-09-30 | United States | Healthcare Distribution — Dental and Medical | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Group of acquisitions from Darby Group Companies completed 2006-06-30 and during Q3 2006 (dental merchandise/equipment distributor, dental lab distributor, and medical supplies/pharmaceuticals provider) with combined annual revenues of approximately $219.0 million; $13.3 million of goodwill recorded. Headcount added not disclosed. | |||
| 2006-09-30 | acquisition_addition | completed | 2006-03-31 | 2006-03-31 | United States | Healthcare distribution — Medical (animal health) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of NLS Animal Health, a full-service animal health distributor with annual revenues of approximately $110.0 million; no employee headcount disclosed. | |||
| 2006-09-30 | divestiture_reduction | completed | 2006-04-01 | 2006-04-01 | United States | Healthcare distribution — Hospital Supply Business | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of substantially all assets of the Hospital Supply Business for $36.5 million; reported as a discontinued operation. No employee headcount associated with the sale is disclosed. | |||
| 2006-09-30 | acquisition_addition | completed | 2006-09-30 | 2006-09-30 | United States | Healthcare distribution — Dental and Medical | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Darby Group acquisitions completed during the third quarter of 2006 (a dental lab distributor and a medical supplies/pharmaceuticals distributor) with combined annual revenues of approximately $219.0 million; no employee headcount disclosed. A June 30, 2006 dental distributor asset acquisition is also noted without headcount. | |||
| 2006-07-01 | acquisition_addition | completed | 2006-03-31 | United States | Healthcare distribution — Medical (animal health) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of NLS Animal Health, a full-service animal health distributor with annual revenues of approximately $110.0 million; $50.9 million of goodwill recorded. Headcount added not disclosed. | ||||
| 2006-07-01 | acquisition_addition | completed | 2006-06-30 | United States | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of certain assets and liabilities of Island Dental Co., Inc., a dental merchandise and equipment distributor with annual revenues of approximately $84.0 million; $4.7 million of goodwill recorded. Headcount added not disclosed. | ||||
| 2006-07-01 | divestiture_reduction | completed | 2006-04-01 | United States | Healthcare distribution — Hospital Supply Business | USD 32 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of substantially all assets of the Hospital Supply Business for $36.5 million; $32.3 million pre-tax loss ($19.4 million after-tax) recorded in discontinued operations. Classified as discontinued operations for all periods presented. Headcount removed not disclosed; contingent payments to buyer of up to $13.0 million. | |||
| 2006-04-01 | acquisition_addition | completed | 2006-03-31 | 2006-03-31 | United States | Healthcare distribution — veterinary (medical) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of NLS Animal Health (annual revenues approx. $110.0 million) completed March 31, 2006; headcount added not disclosed. NLS operating results reflected beginning with the quarter ending July 1, 2006. | |||
| 2006-04-01 | divestiture_reduction | completed | 2006-04-01 | 2006-04-01 | United States | Healthcare distribution — Hospital Supply Business | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of substantially all assets of the Hospital Supply Business on April 1, 2006 for $36.5 million; classified as discontinued operations. Headcount removed not disclosed. Contingent payments up to $13.0 million to buyer over post-closing periods. | |||
| 2006-04-01 | acquisition_addition | completed | 2006-03-31 | Healthcare distribution | USD 49 (millions) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of NLS Animal Health completed. Headcount not disclosed. | ||||
| 2006-04-01 | divestiture_reduction | completed | 2006-04-01 | Healthcare distribution | USD -32 (millions) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Sale of Hospital Supply Business assets. Headcount not disclosed. | ||||
| 2005-12-31 | divestiture_reduction | in_progress | 2005-09-24 | Hospital Supply Business (healthcare distribution segment); sale also includes extended care business | USD 12 (millions) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Decision to divest reached in Q3 2005 (quarter ended 2005-09-24) because the business lacks synergies with core office-based operations. $11.9 million pre-tax ($7.0 million after-tax) impairment charge recorded in Q3 2005 for full write-down of long-lived assets, including $4.6 million of goodwill. Subsequent event: on March 6, 2006, agreement signed to sell substantially all assets for $40.0 million, with expected loss on disposal of $21.0-$24.0 million net of tax at closing; closing conditioned on buyer financing. Headcount of the divested business not disclosed. | ||||
| 2005-12-31 | acquisition_addition | completed | 2005-01-11 | 2005-01-11 | Canada (Ontario) | Dental distribution | USD 17 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Ash Temple Limited, a dental distributor with approximately $100.0 million annual revenues; $16.5 million of goodwill recorded. Headcount added not disclosed. | ||
| 2005-12-31 | acquisition_addition | completed | 2005-04-18 | 2005-04-18 | Austria | Dental distribution (Austrodent) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Regulatory approval received to close the Demedis Group's Austrian (Austrodent) business, contingent on divesting a portion at closing; $8.6 million added to goodwill. Headcount added not disclosed. | |||
| 2005-12-31 | acquisition_addition | completed | Australia, New Zealand, United States | Healthcare distribution | USD 12 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Other 2005 acquisitions recorded approximately $11.5 million of goodwill through preliminary purchase price allocations; described as immaterial individually and in the aggregate. Headcount added not disclosed. | ||||
| 2005-12-31 | divestiture_reduction | in_progress | 2005-09-24 | United States | Hospital Supply Business (healthcare distribution) | USD 12 (millions) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Decision reached in Q3 2005 (quarter ended 2005-09-24) to divest; $11.9 million pre-tax ($7.0 million after-tax) impairment of long-lived assets including $4.6 million goodwill. Subsequent event: sale agreement signed 2006-03-06 for $40.0 million, with expected after-tax disposal loss of $21-24 million ($0.24-$0.27 per diluted share) at closing, plus contingent payments up to $13.0 million. Headcount affected not disclosed. | |||
| 2005-09-24 | divestiture_reduction | in_progress | 2005-09-24 | 2006-09-24 | United States | Healthcare distribution — Hospital Business | USD 12 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision to divest hospital supply business reached during Q3 2005; includes $11.9M pre-tax impairment of long-lived assets including $4.6M goodwill; expected sale within 12 months; no employee count disclosed | ||
| 2005-09-24 | acquisition_addition | completed | 2005-01-11 | 2005-01-11 | Canada | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Ash Temple Limited dental distribution business, annual revenues approximately $100.0 million, 14 branches; headcount added not disclosed | |||
| 2005-09-24 | acquisition_addition | completed | 2005-04-18 | 2005-04-18 | Austria | Healthcare distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Regulatory approval of Demedis Group's Austrodent business acquisition, contingent on divesting a portion at closing; headcount added not disclosed | |||
| 2005-09-24 | acquisition_addition | completed | 2005-09-24 | 2005-09-24 | Australia, New Zealand, United States | Other | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Other smaller acquisitions completed during the nine months, immaterial individually and in aggregate; approximately $8.5 million of goodwill recorded; headcount added not disclosed | |||
| 2005-06-25 | acquisition_addition | completed | 2005-01-11 | 2005-01-11 | Canada (Ontario) | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Ash Temple Limited dental distribution business, annual revenues approx. $100 million, 14 branches; no employee count disclosed. Occurred in Q1 of fiscal 2005 (year-to-date period). | |||
| 2005-06-25 | acquisition_addition | completed | 2005-04-18 | Austria | Healthcare distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Regulatory approval received 2005-04-18 for acquisition of Demedis Group's Austrodent business; closing occurred during the six months ended 2005-06-25 (exact closing date not stated). No employee count disclosed. | ||||
| 2005-06-25 | divestiture_reduction | completed | 2005-04-18 | Austria | Healthcare distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approval of Austrodent acquisition was conditioned on divesting a portion of the business at closing; approx. $2.1 million received for the divested portion. No employee count disclosed. | ||||
| 2005-03-26 | acquisition_addition | completed | 2005-01-11 | Canada (Ontario) | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired Jan 11, 2005; business with annual revenues of approximately $100 million and 14 branches. Headcount added not disclosed; operations combined with Henry Schein Arcona as Henry Schein Ash Arcona. Three other small acquisitions in the quarter also recorded goodwill but were not material individually or in aggregate. | ||||
| 2005-03-26 | acquisition_addition | announced | 2005-04-18 | Austria | Healthcare distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Regulatory approval received April 18, 2005 (subsequent to quarter end), contingent on divesting part of Austrodent's business and other restrictions. EUR 11.0 million ($13.5 million) of purchase price held in other current assets at March 26, 2005. Headcount to be added not disclosed. | ||||
| 2004-12-25 | acquisition_addition | completed | 2004-06-18 | 2004-06-18 | Germany, Austria, Benelux countries, Italy | Healthcare distribution — international dental | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired the Demedis Group (Demedis GmbH, excluding Austrian operations, and Euro Dental Holding GmbH, including KRUGG S.p.A. and DentalMV GmbH) on June 18, 2004; cash paid was approximately EUR 51.8 million ($62.9 million) after giving effect to the M&W divestiture proceeds. Employee headcount added through the acquisition was not disclosed. The Austrian operations (Austrodent, EUR 11.0 million / $13.5 million) remained pending regulatory approval at fiscal year-end and are excluded from this completed action. | |||
| 2004-12-25 | divestiture_reduction | completed | 2004-07-16 | 2004-07-16 | Germany | Healthcare distribution — international dental | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Divested DentalMV GmbH (Muller & Weygandt, 'M&W') on July 16, 2004 for EUR 50.0 million ($62.2 million) including assumed debt, as required by German regulatory authorities as a condition of the Demedis Group acquisition. Employee headcount removed was not disclosed. M&W was subsequently resold in September 2004, with Henry Schein realizing a EUR 26.4 million ($32.4 million) share of net proceeds treated as a further purchase-price reduction. | |||
| 2004-12-25 | acquisition_addition | completed | 2004-06-18 | 2004-06-18 | Germany, Austria, Benelux, Italy | Healthcare Distribution — International | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of the Demedis Group (Demedis GmbH excluding Austrian operations, Euro Dental Holding GmbH including KRUGG S.p.A. and DentalMV GmbH/M&W). No employee headcount added is disclosed. | |||
| 2004-12-25 | divestiture_reduction | completed | 2004-07-16 | 2004-07-16 | Germany | Healthcare Distribution — International | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Divestiture of DentalMV GmbH (Muller & Weygandt) completed for EUR 50.0 million as required by German regulatory authorities as a condition of the Demedis acquisition; no employee headcount removed is disclosed. | |||
| 2004-09-25 | acquisition_addition | completed | 2004-06-18 | 2004-06-18 | Europe (Germany, Austria, Benelux, Italy) | Healthcare distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Demedis Group (Demedis GmbH, Euro Dental Holding/KRUGG, DentalMV) closed 2004-06-18; operating results consolidated from that date. Headcount added not disclosed. | |||
| 2004-09-25 | divestiture_reduction | completed | 2004-07-16 | 2004-07-16 | Germany | Healthcare distribution — International (Muller & Weygandt) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Required divestiture of DentalMV/Muller & Weygandt as a condition of German regulatory approval of the Demedis acquisition; completed for EUR 50.0 million. Headcount removed not disclosed. | |||
| 2004-09-25 | acquisition_addition | completed | 2004-07-02 | 2004-07-02 | Switzerland | Healthcare distribution — International (dental implants) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 50.1% of Camlog Holding AG; final payment made 2004-07-02, operating results consolidated from close. Headcount added not disclosed. | |||
| 2004-06-26 | acquisition_addition | completed | 2004-01-08 | 2004-06-18 | Germany, Austria, Benelux, Italy | Healthcare Distribution — International | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Demedis Group acquired June 18, 2004 for ~EUR 259.5M ($315.5M); no headcount impact disclosed | |||
| 2004-06-26 | divestiture_reduction | completed | 2004-06-18 | 2004-07-16 | Germany | Healthcare Distribution — International (Muller & Weygandt) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | M&W divestiture required by German regulators as condition of Demedis acquisition; completed July 16, 2004 for EUR 50.0M; no headcount impact disclosed | |||
| 2004-06-26 | acquisition_addition | completed | 2004-01-01 | 2004-07-02 | Switzerland | Healthcare Distribution — Dental (Camlog Holding AG) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Camlog acquisition (50.1% equity) closed July 2, 2004; ~$43.0M paid in Q1 2004; no headcount impact disclosed | |||
| 2004-03-27 | acquisition_addition | in_progress | 2004-01-08 | 2004-06-30 | Germany, Austria, Benelux, Italy | Healthcare distribution (dental) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreements to acquire demedis GmbH and Euro Dental Holding GmbH; no employee counts disclosed. Awaiting German and Austrian regulatory review; 35 million euros paid January 2004 toward a roughly 255 million euro price. | |||
| 2004-03-27 | acquisition_addition | in_progress | 2004-12-31 | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Separate pending acquisition; approximately $43 million paid during the quarter toward a purchase price requiring only a nominal payment at closing, expected in 2004. No announcement date or employee counts disclosed. | ||||||
| 2004-03-27 | acquisition_addition | completed | Technology | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | One technology business acquired during the quarter, adding approximately $2.0 million of goodwill; no employee counts disclosed. An earn-out payment on a prior healthcare distribution acquisition added roughly $1.6 million of goodwill. | ||||||
| 2003-12-27 | acquisition_addition | completed | United States and Germany | Healthcare distribution | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Eight healthcare distribution businesses acquired during fiscal 2003; none considered material individually or in aggregate. Named transactions: Hager Dental GmbH (Germany, 2003-05-28), Colonial Surgical Supply, Inc. (US, 2003-06-02), Damer & Cartwright Pharmaceutical, Inc. and American Medical Services, Inc. (US, 2003-11-17). No employee headcount disclosed for acquired businesses. | |||||
| 2003-12-27 | divestiture_reduction | completed | 2003-08-29 | 2003-08-29 | Germany | Healthcare distribution | USD 2 (millions) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Sold PMA Bode GmbH, an x-ray film distribution business, on 2003-08-29; the business generated roughly $31.0 million in annual net sales. A loss of $2.0 million net of tax was recorded on the sale; this is the divestiture loss, not a severance charge. No employee headcount disclosed for the divested operation. | ||
| 2003-12-27 | acquisition_addition | announced | 2004-01-08 | Germany, Austria, Benelux countries, Italy | Healthcare distribution — International | subsequent_events f5-10k / GLM-5.3-flash-HTML | Subsequent event disclosed in Note 7: agreements signed 2004-01-08 to acquire demedis GmbH and Euro Dental Holding GmbH (including KRUGG S.p.A. and DentalMV GmbH) for approximately 255 million euros. A 35 million euro deposit was paid 2004-01-20, with roughly 220 million euros due at closing. Closing expected mid-2004, subject to regulatory approval; expected to approximately double international segment net sales. No employee headcount disclosed. | ||||
| 2003-12-27 | acquisition_addition | completed | United States, Germany | Healthcare Distribution | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Eight healthcare distribution businesses acquired during fiscal 2003; headcount added not disclosed. Named transactions: Hager Dental GmbH (2003-05-28), Colonial Surgical Supply (2003-06-02), Damer & Cartwright Pharmaceutical and American Medical Services (2003-11-17). Aggregate acquisition consideration $155.0 million with $36.8 million of assumed liabilities. | |||||
| 2003-12-27 | divestiture_reduction | completed | 2003-08-29 | 2003-08-29 | Germany | Healthcare Distribution — x-ray film distribution (PMA Bode GmbH) | USD 2 (millions) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | PMA Bode generated annual net sales of approximately $31.0 million; $2.0 million loss net of tax recorded as loss on sale of discontinued operation. Employees affected not disclosed. | ||
| 2003-12-27 | acquisition_addition | announced | 2004-01-08 | 2004-06-30 | Europe (Germany, Austria, Benelux, Italy) | Healthcare Distribution — International | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Agreements to purchase demedis GmbH and Euro Dental Holding GmbH for approximately 255 million euros; 35 million euros deposit paid 2004-01-20, approximately 220 million euros due at closing. Expected to approximately double international net sales; headcount added not disclosed. Expected to close mid-year 2004. | |||
| 2003-09-27 | acquisition_addition | completed | 2003-05-28 | Germany | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Hager Dental GmbH, a German dental distributor; acquired 2002 net sales of approximately $50.0 million. No employee headcount impact disclosed. | ||||
| 2003-09-27 | acquisition_addition | completed | 2003-06-02 | United States | Healthcare distribution — Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Asset acquisition of Colonial Surgical Supply, Inc.; acquired 2002 net sales of approximately $40.0 million. Agreement provides for up to $10.0 million additional cash consideration if profitability targets are met. No employee headcount impact disclosed. | ||||
| 2003-09-27 | divestiture_reduction | completed | 2003-08-29 | 2003-08-29 | Germany | Healthcare distribution — International (x-ray film distribution) | USD 2 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Divestiture of PMA Bode GmbH, an x-ray film distribution business; annual net sales of approximately $31.0 million. Loss on sale of approximately $2.0 million net of tax benefit, reported as loss on discontinued operation. No employee headcount impact disclosed. | ||
| 2003-06-28 | restructuring | in_progress | 2 | 2000-08-01 | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Two employees received severance payments during the six months ended June 28, 2003, related to a restructuring plan announced August 1, 2000. | ||||
| 2003-06-28 | acquisition_addition | completed | 2003-05-28 | Germany | Healthcare Distribution | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquired Hager Dental GmbH on May 28, 2003. Employee count not disclosed. | ||||
| 2003-06-28 | acquisition_addition | completed | 2003-06-02 | United States | Healthcare Distribution | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquired assets of Colonial Surgical Supply, Inc. on June 2, 2003. Employee count not disclosed. | ||||
| 2003-03-29 | restructuring | in_progress | 2 | 2000-08-01 | United States | USD 265 (thousands) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Two employees received severance payments during Q1 2003 under a restructuring plan originally announced August 1, 2000; both still owed severance pay and benefits at quarter-end. Payments of $265K were made against the $3,044K accrual during the quarter. | |||
| 2003-03-29 | restructuring | in_progress | 2 | 2000-08-01 | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Two employees received severance payments during the quarter and were still owed severance pay and benefits as of March 29, 2003. Related to restructuring plan announced August 1, 2000. | ||||
| 2002-12-28 | restructuring | in_progress | Worldwide | All functions | USD 0 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2002 revision of estimates under the August 2000 restructuring plan; includes ~$0.1M severance and ~$0.3M facility closing costs. No FY2002 employee count disclosed; the ~300 positions eliminated relate to the original 2000 plan announcement. | ||||
| 2002-12-28 | acquisition_addition | completed | Europe | Healthcare distribution | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2002: one healthcare distribution business acquired plus additional interests in three European subsidiaries; described as not material individually or in aggregate. No headcount disclosed. | |||||
| 2002-12-28 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels within the organization | USD 0 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Plan announced in 2000 to eliminate approx. 300 positions (5% of workforce). Substantially completed in 2000. In 2002, company recorded additional expenses of $0.4 million due to revised estimates of anticipated restructuring expenses from the original plan. |
| 2002-09-28 | restructuring | in_progress | 6 | 2000-08-01 | Worldwide | All segments | USD 877 (thousands) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Payments of $877 thousand (severance $392K, facility closing $484K, other $1K) were made against the restructuring accrual during the nine months ended September 28, 2002; six employees received severance in the period and one was still owed severance at period end. The plan, announced August 1, 2000, eliminated approximately 300 positions (about 5% of the workforce) and was substantially completed at December 30, 2000; accrual balance was $2,442 thousand at September 28, 2002. Employees_affected_count reflects severance recipients during the current nine-month period, not the original program scope. | ||
| 2002-09-28 | restructuring | in_progress | 1 | All segments | USD 682 (thousands) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Payments of $682 thousand were made against the merger and integration accrual during the nine months ended September 28, 2002 (severance and other direct costs $161K; direct transaction and other integration costs $521K). One employee received severance in the period and was still owed severance at September 28, 2002; accrual balance was $1,866 thousand at period end. Relates to prior years' acquisitions. | ||||
| 2002-09-28 | restructuring | in_progress | 1 | 2000-08-01 | USD 241 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | One employee owed severance at period end; total restructuring accrual balance $2,442k. | ||||
| 2002-09-28 | restructuring | in_progress | 1 | 2000-08-01 | USD 204 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | One employee owed severance at period end related to prior acquisitions; total merger/integration accrual balance $1,866k. | ||||
| 2002-06-29 | restructuring | in_progress | 2000-08-01 | Global | All segments | USD 621 (thousands) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Legacy restructuring announced Aug 2000, substantially completed Dec 2000; ~300 positions eliminated (~5% of workforce). During six months ended Jun 29, 2002, four employees received severance and one was owed severance. Remaining accrual balance $2,698K at quarter-end. | |||
| 2002-06-29 | restructuring | in_progress | Global | All segments | USD 540 (thousands) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Merger and integration costs from prior-year acquisitions. During six months ended Jun 29, 2002, one employee received severance. Remaining accrual balance $2,008K at quarter-end. | ||||
| 2002-06-29 | restructuring | in_progress | 1 | 2000-08-01 | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | One employee owed severance at June 29, 2002. Four employees received severance during the six months ended June 29, 2002. Original plan announced Aug 1, 2000. | ||||
| 2002-06-29 | restructuring | in_progress | 1 | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | One employee owed severance at June 29, 2002 related to prior acquisitions. One employee received severance during the six months ended June 29, 2002. | |||||
| 2002-03-30 | restructuring | in_progress | 10 | 2000-08-01 | World-wide | All levels | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Six employees received severance payments and four were owed severance pay and benefits during the quarter. The plan, announced in August 2000, eliminated approx. 300 positions total. | ||
| 2002-03-30 | restructuring | in_progress | 1 | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | One employee received severance and one was owed severance at quarter-end related to prior acquisitions. | |||||
| 2001-12-29 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels and functions across the organization | USD 14 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Plan announced August 1, 2000 eliminating approximately 300 positions including open positions (~5% of workforce); substantially completed December 30, 2000. Fiscal 2000 charge of $14.4M comprised ~$7.2M severance, ~$4.4M facility closing, ~$2.8M professional fees; no restructuring charges recorded in fiscal 2001. Residual fiscal 2001 activity: 104 separated employees received severance payments and 6 remained owed severance at December 29, 2001. |
| 2001-12-29 | restructuring | completed | 870 | Acquisition integration, including closure of distribution centers | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Cumulative through fiscal year-end 1999: 870 employees terminated as a result of acquisitions and integration into company infrastructure. Residual fiscal 2001 activity: 11 employees received severance during 2001 and 1 remained owed severance at December 29, 2001. Related merger and integration costs of $13.5M were recorded in fiscal 1999 (prior year). | |||||
| 2001-12-29 | restructuring | completed | 104 | 2000-08-01 | 2000-12-30 | Worldwide | All levels within the organization | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program announced in prior fiscal year (FY2000) eliminated approximately 300 positions with a $14.4 million charge; substantially completed December 30, 2000. Current-year activity captured: 104 employees received severance payments during fiscal 2001 and 6 employees were still owed severance at year-end (accrual balance $3.3 million). No restructuring charge was recorded in fiscal 2001. | ||
| 2001-12-29 | acquisition_addition | completed | Healthcare distribution | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Two healthcare distribution businesses acquired during fiscal 2001 (including purchase of remaining 50% interest of an affiliate); neither considered material individually or in aggregate and no headcount added disclosed | ||||||
| 2001-12-29 | restructuring | completed | 11 | Integration of acquired businesses | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Current-year severance payments to 11 employees under the multi-year merger/integration program (870 employees terminated cumulatively through 1999); 1 employee remained owed severance at fiscal year-end | |||||
| 2001-12-29 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels | USD 14 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Announced Aug 1, 2000. Elimination of approx 300 positions (5% of workforce). Substantially completed at Dec 30, 2000. Costs incurred in FY2000. |
| 2001-09-29 | restructuring | in_progress | 104 | 2000-08-01 | Global | All levels within the organization | USD 3,573 (thousands) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Restructuring plan announced Aug 1, 2000, originally eliminating ~300 positions (~5% of workforce); substantially completed Dec 30, 2000. During nine months ended Sep 29, 2001, 104 employees received severance and 17 were still owed severance at period end. Severance payments during period totaled $3,573K; total restructuring accrual payments were $4,711K including facility closing and professional costs. | ||
| 2001-09-29 | restructuring | in_progress | 11 | Merger and integration | USD 344 (thousands) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance related to prior-year acquisitions. During nine months ended Sep 29, 2001, 11 employees received severance and 1 was owed severance at period end. Severance and other direct cost payments during period totaled $344K. | ||||
| 2001-09-29 | acquisition_addition | announced | 2001-11-05 | Dental distribution | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Zila, Inc. full-service dental distribution operations in all-cash transaction. Zila's dental distribution had ~$21.0M net sales for twelve months ended Jul 31, 2001. No headcount disclosed; no one-time charges expected. | |||||
| 2001-09-29 | restructuring | in_progress | 115 | 2000-08-01 | World-wide | All levels within the organization | USD 4,137 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 104 employees received severance and 17 were owed severance at September 29, 2001. Original plan eliminated approx 300 positions. | ||
| 2001-09-29 | restructuring | in_progress | 12 | USD 3,352 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Merger and integration costs. 11 employees received severance and 1 was owed severance at September 29, 2001. | |||||
| 2001-06-30 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels within the organization | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approximately 300 positions (about 5% of workforce) eliminated; plan substantially completed at 2000-12-30. Severance payments continued in H1 2001: 104 employees received severance and 23 were owed severance at 2001-06-30. Restructuring accrual fell from $8,848K to $4,816K during the six months. | |
| 2001-06-30 | other | in_progress | 11 | Prior-year acquisitions (merger and integration) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance paid in H1 2001 related to prior years' acquisitions: 11 employees received severance and 3 were owed severance at 2001-06-30; merger and integration accrual of $4,887K reduced to $3,690K. | |||||
| 2001-06-30 | restructuring | completed | 115 | 2000-08-01 | 2000-12-30 | World-wide | All levels within the organization | USD 4,816 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Plan announced Aug 1, 2000 to eliminate approx 300 positions. Substantially completed Dec 30, 2000. During the six months ended June 30, 2001, 104 employees received severance and 23 were owed severance at June 30, 2001. Remaining accrual balance $4,816k. | |
| 2001-06-30 | restructuring | completed | 14 | USD 470 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Merger and integration costs. During the six months ended June 30, 2001, 11 employees received severance and 3 were owed severance at June 30, 2001. Remaining accrual balance $470k. | |||||
| 2001-03-31 | restructuring | in_progress | 104 | 2000-08-01 | Worldwide | All levels within the organization | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program announced 2000-08-01 eliminated ~300 positions (about 5% of workforce) and was substantially completed by 2000-12-30. During Q1 2001, 104 employees received severance; 74 were owed severance at 2001-03-31. Restructuring accrual payments in Q1 2001 totaled $1.6M (severance, facility closing, professional/consulting). | |||
| 2001-03-31 | restructuring | in_progress | 11 | Prior-year acquisitions (merger and integration) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance and other direct costs related to prior-year acquisitions: 11 employees received severance during Q1 2001; 4 were owed severance at 2001-03-31. Payments against merger/integration accrual totaled $0.7M in the quarter. | |||||
| 2001-03-31 | restructuring | in_progress | 115 | 2000-08-01 | World-wide | All levels | USD 1,600 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 104 employees received severance and 74 were owed severance at March 31, 2001. Total payments against accrual were $1.6 million. Original plan (Aug 2000) eliminated approx 300 positions. | ||
| 2001-03-31 | restructuring | in_progress | 15 | USD 184 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Merger and integration costs. 11 employees received severance and 4 were owed severance at March 31, 2001. Payments of $184k. | |||||
| 2000-12-30 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | World-wide | All levels within the organization; included closing or downsizing certain facilities | USD 14 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Announced August 1, 2000; implemented over the last five months of 2000 and substantially completed at December 30, 2000. Positions eliminated included open positions. Charge comprised approximately $7.2M severance pay and benefits, $4.4M facility closing costs (primarily lease termination and asset write-offs) and $2.8M outside professional/consulting fees ($9.3M after taxes, ~$0.22 per diluted share). During fiscal 2000, 284 employees separated and received severance and 104 were owed severance pay at year-end (restructuring accrual balance of $8.8M). Estimated annual pre-tax savings of ~$20.0M (~$0.29 per diluted share). |
| 2000-12-30 | other | in_progress | 37 | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Involuntary terminations arising from integration of previously acquired businesses into the Company's infrastructure. Cumulative 870 employees terminated through fiscal year-end 2000 (502 received severance in 1998, 206 in 1999, 37 in 2000); 11 employees remained owed severance at December 30, 2000. Severance payments of approximately $0.9M were made in 2000 against prior-year merger and integration accruals; no new severance provision was recorded in 2000 (total merger and integration costs of $0.585M in 2000 were transaction/merger fees). | ||||||
| 2000-12-30 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels within the organization | USD 14 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Approximately 300 positions including open positions, about 5% of workforce; charge comprises severance $7.2M, facility closures $4.4M, professional fees $2.8M; 284 employees separated and received severance, 104 owed severance at year-end; substantially completed at fiscal year-end |
| 2000-12-30 | divestiture_reduction | completed | 2000-11-27 | 2000-11-27 | United Kingdom | Technology — software development business unit | USD 2 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | UK subsidiary sold its practice management software development unit; non-recurring loss of approximately $1.6M; headcount not disclosed | ||
| 2000-12-30 | divestiture_reduction | completed | 2000-10-23 | 2000-10-23 | United States / Canada | Healthcare distribution — 50% interest in HS Pharmaceutical Inc. (Novocol) | USD 2 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of 50% interest in dental anesthetic manufacturer to co-owner Deproco; unconsolidated affiliate so headcount was likely outside reported total; non-recurring net charge approximately $1.9M | ||
| 2000-12-30 | acquisition_addition | completed | 2000-12-30 | United States | Healthcare distribution and technology | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Three acquisitions completed in fiscal 2000 (two healthcare distribution, one technology), none material individually or in aggregate; headcount added not disclosed | ||||
| 2000-12-30 | restructuring | completed | 300 | 5% | 2000-08-01 | 2000-12-30 | World-wide | All levels within the organization | USD 14 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Elimination of approximately 300 positions, including open positions. Plan substantially completed at December 30, 2000. |
| 2000-09-23 | restructuring | in_progress | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels and functional areas of the organization | USD 14 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approximately 300 positions (including open positions), about 5% of total workforce. Roughly $5.4M incurred through Q3 2000 ($3.4M after taxes, ~$0.08/diluted share) and about $8.6M expected in Q4 2000 ($5.0M after taxes, ~$0.12/diluted share), when the plan will be substantially complete. Through Q3, 164 employees were separated and 105 were owed severance at 2000-09-23. Of the $5.4M incurred, about $0.4M related to the Technology segment. Estimated annual pre-tax savings of ~$20.0M ($12.0M after taxes, ~$0.29/diluted share) from this plan plus a previously announced dental rightsizing plan. |
| 2000-09-23 | other | in_progress | 40 | Merger and integration activities related to pooling-of-interests acquisitions (2000, 1999 and 1998) | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance tied to merger/integration costs: 40 employees received severance during the nine months ended 2000-09-23 and 14 were owed severance at quarter end. Merger and integration costs of $585 thousand were provided in the nine-month period (nil in Q3). | ||||
| 2000-09-23 | divestiture_reduction | announced | 2000-10-23 | United States / Canada | Dental anesthetic manufacturing (50% interest in HS Pharmaceutical, owner of Novocol Pharmaceutical of Canada, Inc.) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of 50% interest announced after quarter end to sharpen focus on core value-added distribution business; expected non-recurring loss of approximately $0.05 per share in Q4 2000. No headcount impact disclosed. | ||||
| 2000-09-23 | restructuring | in_progress | 300 | 5% | 2000-08-01 | 2000-12-31 | Worldwide | All levels within the organization | USD 5 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Includes elimination of approx 300 positions (including open positions). Incurred one-time costs of approx $5.4 million in Q3 (severance, facility closing, professional fees). Expects additional $8.6 million in Q4. |
| 2000-06-24 | restructuring | announced | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | Company-wide | USD 14 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced August 1, 2000, after quarter end. Worldwide initiative eliminating approximately 300 positions (about 5% of the workforce) at all levels; one-time pre-tax charge of about $14.0 million ($8.4 million after tax), or $0.20 per diluted share, expected in the second half of 2000, primarily severance, facility closing costs and consulting fees. Implied workforce total from the 5% figure is not stated by the filer. |
| 2000-06-24 | other | in_progress | 39 | Merger integration (pooling-of-interests transactions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance related to pooling-of-interests merger integration: 39 employees received severance during the six months ended June 24, 2000, and 17 were owed severance at period end. Related merger and integration accrual rolled from $10,093 thousand to $6,729 thousand during the period; charge covers compensation, rent and other integration costs, not severance alone. | |||||
| 2000-06-24 | acquisition_addition | completed | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Three acquisitions completed during the six months ended June 24, 2000 (two purchase-method, one pooling-of-interests); none deemed material and headcount added was not disclosed. | |||||||
| 2000-06-24 | restructuring | announced | 300 | 5% | 2000-08-01 | 2000-12-30 | Worldwide | All levels | USD 14 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Comprehensive restructuring plan to improve customer service and profitability. Charge includes severance, facility closing costs, and professional fees. |
| 2000-06-24 | restructuring | in_progress | 39 | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Severance related to prior merger and integration activities. 39 employees received severance during the six months ended June 24, 2000. | ||||||
| 2000-03-25 | restructuring | in_progress | 33 | USD 0 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Severance paid during Q1 2000 under integration of prior-year pooling acquisitions; 33 employees received severance and 24 were owed severance at 2000-03-25. Severance and other direct costs paid in the period totaled $370 thousand; an additional $1,324 thousand remained accrued at quarter-end. | |||||
| 2000-03-25 | restructuring | in_progress | 33 | USD 370 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Severance payments of $370k made during Q1 2000 related to prior year acquisitions. 33 employees received severance; 24 owed at quarter end. | |||||
| 1999-12-25 | restructuring | completed | 206 | Company-wide (integration of acquired businesses into Company infrastructure) | USD 3,437 (thousands) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition-integration terminations attributable to fiscal 1999: 206 employees received severance during 1999. Cumulative program through Dec 25, 1999: 870 employees terminated (129 in 1997, 502 in 1998, 206 in 1999), with 33 still owed severance at year-end and $1,694 thousand severance accrual remaining. 1999 integration costs also included $5,583 thousand of distribution-center closure costs (primarily rent and consulting fees). | ||||
| 1999-12-25 | restructuring | in_progress | 206 | North America, Europe, Australia | Healthcare distribution and technology (acquisition integration) | USD 13 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 206 employees received severance payments during FY1999 as part of ongoing acquisition integration; cumulative program total of 870 terminated through FY1999 year-end, with 33 still owed severance at 1999-12-25. Charge includes $13.467M total merger and integration costs for FY1999. | |||
| 1999-12-25 | acquisition_addition | completed | United States, Germany, United Kingdom, other international | Healthcare distribution (medical, dental, veterinary, international) | USD 139 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Nine acquisitions completed in FY1999 with aggregate 1998 net sales of approximately $324.0 million; headcount added not disclosed. Aggregate purchase price approximately $139.0 million ($132.6M cash, $6.4M stock). | ||||
| 1999-12-25 | restructuring | completed | 206 | 1999-12-25 | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 206 employees received severance payments during 1999 as part of integration of acquired businesses. Part of a multi-year program totaling 870 terminations through Dec 25, 1999. | |||||
| 1999-09-25 | acquisition_addition | completed | United States; Germany | Healthcare distribution (medical, dental, veterinary, international) | USD 149 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Eight acquisitions completed in the nine months ended 1999-09-25 (seven purchase-method, one pooling); named targets include General Injectibles and Vaccines and Heiland Group GmbH. No employee counts disclosed; charge shown is total cash purchase price for the seven purchase-method acquisitions. | ||||
| 1999-09-25 | plant_closure | in_progress | Not specified | Healthcare distribution — distribution centers | USD 14 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Integration of pooling-method mergers involved closure of distribution centers; $13.5M merger and integration costs incurred in the nine months ended 1999-09-25 ($15.7M accrued at period end, expected to be paid within a year). No employee counts or closure dates disclosed. | ||||
| 1999-09-25 | restructuring | in_progress | 2000-09-25 | USD 15,739 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Merger and integration costs accrued at Sept 25, 1999 consist primarily of severance, professional and consulting fees, and rent. Company expects substantially all costs to be paid within the next year. | |||||
| 1999-06-26 | restructuring | in_progress | 1999-12-31 | USD 13,901 (thousands) | financial_statements f5-10q / Qwen3.6-27B-Q8_0 | Accrued merger and integration costs of $13.9 million as of June 26, 1999, consisting primarily of severance, stay-bonuses, and rent. Company expects these amounts to be paid in 1999. | |||||
| 1999-06-26 | acquisition_addition | completed | United States; Germany | Healthcare Distribution | USD 149,295 (thousands) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed eight acquisitions during the six months ended June 26, 1999, including General Injectibles and Vaccines, Inc. (GIV) and Heiland Group GmbH. Total cash purchase price for seven acquisitions was approximately $149.3 million. Employee headcount added is not disclosed. | ||||
| 1999-03-27 | acquisition_addition | completed | United States and international | Healthcare distribution | USD 143 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Five purchase-method acquisitions completed in Q1 1999, including General Injectibles and Vaccines, Inc. and Heiland Group GmbH; purchase price disclosed but no employee counts given. | ||||
| 1999-03-27 | acquisition_addition | completed | 1999-02-23 | United States | Healthcare distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | One pooling-of-interests acquisition; 231,304 shares issued with aggregate value of approximately $6.4 million; no headcount disclosed. | ||||
| 1999-03-27 | restructuring | in_progress | 1999-12-31 | USD 2,203 (thousands) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Merger and integration costs incurred for Q1 1999. Accrued amounts consist primarily of severance, stay-bonuses and rent, which will be paid during 1999. | |||||
| 1999-03-27 | acquisition_addition | completed | United States; Germany | Healthcare Distribution | USD 142,750 (thousands) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Completed six acquisitions in Q1 1999, including General Injectibles and Vaccines, Inc. and Heiland Group GmbH. Five accounted for under purchase method ($142.8M cash); one under pooling ($6.4M stock). Headcount not disclosed. | ||||
| 1998-12-26 | restructuring | in_progress | Healthcare distribution and technology; integration of acquired dental and medical businesses | USD 12,366 (thousands) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Severance and other direct costs of approximately $12.4 million incurred in fiscal 1998 for integration of acquisitions, primarily the 1998 Meer pooling and the 1997 Sullivan, MBMI and Dentrix poolings. Year-end accruals (primarily severance, stay bonuses and rent) payable during 1999; additional charges expected in subsequent periods. Affected-employee count not disclosed. | |||||
| 1998-12-26 | plant_closure | in_progress | Healthcare distribution — distribution facility consolidation | USD 15,400 (thousands) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Costs associated with the closure of distribution centers, primarily rent and consulting fees, incurred as part of the merger and integration program. Item 2 states the Company is in the process of consolidating its distribution facilities. Affected-employee count not disclosed. | |||||
| 1998-12-26 | divestiture_reduction | completed | 1998-08-07 | Dental equipment manufacturing (Marus Dental International) | Item_1_Business f5-10k / GLM-5.3-flash-HTML | Sale of Marus Dental International, the Company's dental equipment manufacturing operation, completed August 7, 1998; Marus had 1997 net sales of approximately $25.0 million. Headcount removed not disclosed. | |||||
| 1998-12-26 | acquisition_addition | completed | Dental, medical and international healthcare distribution | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Five acquisitions completed during fiscal 1998: two dental supply companies (most significantly H. Meer Dental Supply Co., effective August 14, 1998), two medical supply companies and one international dental distribution business. Headcount added not disclosed. | ||||||
| 1998-12-26 | acquisition_addition | completed | 1998-12-28 | Germany | International healthcare distribution | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition of Heiland Holding GmbH (Heiland Group), a Hamburg-based direct marketer of healthcare supplies to office-based practitioners, closed December 28, 1998 (subsequent to fiscal year-end) for approximately $84.0 million; 1998 net sales approximately $130.0 million. Date shown is the completion date. Headcount added not disclosed. | ||||
| 1998-12-26 | acquisition_addition | completed | 1998-12-31 | United States | Medical distribution — vaccines and injectible products | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition of General Injectibles and Vaccines, Inc. (GIV), via purchase of all outstanding common stock of Biological & Popular Culture, Inc., closed December 31, 1998 (subsequent to fiscal year-end) for approximately $53.5 million; 1998 net sales approximately $120.0 million. Date shown is the completion date. Headcount added not disclosed. | ||||
| 1998-12-26 | restructuring | in_progress | North America, Europe, Australia | Healthcare distribution and technology | USD 57 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY1998 merger/integration program includes $12.366M severance and other direct costs, $15.4M distribution center closure costs, $13.5M asset write-offs, $8.3M signing bonuses, $7.1M transaction costs; no employee counts disclosed | ||||
| 1998-12-26 | divestiture_reduction | completed | 1998-08-07 | United States | Dental equipment manufacturing (Marus Dental International) | Item_1_Business f5-10k / MiMo-V2.6-Flash-fp8-HTML | Marus had 1997 net sales of approximately $25.0 million; operations described as not material; no headcount disclosed | ||||
| 1998-12-26 | acquisition_addition | completed | 1998-12-28 | Germany | Healthcare distribution (international) | USD 84 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Heiland Group acquired for approximately $84.0M; 1998 net sales approximately $130.0M; purchase method; no headcount disclosed | |||
| 1998-12-26 | acquisition_addition | completed | 1998-12-31 | United States | Healthcare distribution (medical/vaccines) | USD 54 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | General Injectibles and Vaccines acquired for approximately $53.5M; 1998 net sales approximately $120.0M; purchase method; no headcount disclosed | |||
| 1998-12-26 | restructuring | completed | 1998-12-26 | 1998-12-26 | Global | Various | USD 57 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Merger and integration costs incurred during the year ended December 26, 1998. Includes severance and other direct costs of $12.4 million and closure of distribution centers. Specific employee count not disclosed. | ||
| 1998-09-26 | acquisition_addition | completed | 1998-08-14 | 1998-08-14 | United States | Dental | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Meer Dental Supply Co. acquired via pooling of interests; 1997 net sales over $180M; no employee count disclosed | |||
| 1998-09-26 | divestiture_reduction | completed | 1998-08-07 | 1998-08-07 | United States | Dental equipment manufacturing | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of Marus Dental International, dental equipment manufacturing operation; 1997 net sales ~$25M; no employee count disclosed | |||
| 1997-09-27 | other | completed | United States | Distribution / Logistics | USD 1 (millions) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Teamsters Union strike against UPS in Q3 1997 disrupted shipments; company incurred ~$1.3M ($0.03/share) in incremental transportation and payroll costs from alternative couriers. Not a company workforce action per se, but a material labor event affecting operations. | ||||
| 1997-09-27 | acquisition_addition | announced | 1997-08-03 | 1997-11-30 | United States | Dental distribution | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Stock-for-stock merger with Sullivan Dental Products announced 1997-08-03, valued ~$285M; expected to close mid-November 1997. Sullivan had 52 sales/service centers and ~$242M 1996 net sales. No employee count disclosed. Company anticipates a $15–20M non-recurring charge in Q4 1997 plus additional 1998 warehouse-integration charges. | |||
| 1997-09-27 | acquisition_addition | completed | United States / International | Medical, dental, international, technology, veterinary distribution | USD 22 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sixteen acquisitions completed in the nine months ended 1997-09-27 (four medical, three dental, five international, three technology, one direct marketer). Five accounted for as poolings (Dentrix and MBMI material). Merger and integration costs of $22.1M (9M) / $17.7M (Q3) incurred. No employee headcount added disclosed. | ||||
| 1997-09-27 | other | completed | United States | Logistics / Operations | USD 1 (millions) | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Teamsters Union strike against UPS resulted in $1.3 million in higher transportation and payroll costs due to alternative shipping arrangements and sorting labor. No specific employee count affected is disclosed. | ||||
| 1997-09-27 | acquisition_addition | completed | 1997-02-28 | United States | Technology / Dental | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Dentrix Dental Systems, Inc. completed. Headcount added is not explicitly disclosed. | ||||
| 1997-09-27 | acquisition_addition | completed | 1997-08-01 | United States | Medical | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Micro Bio-Medics, Inc. (MBMI) completed. Headcount added is not explicitly disclosed. | ||||
| 1997-09-27 | acquisition_addition | announced | 1997-08-03 | 1997-11-15 | United States | Dental | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Merger agreement with Sullivan Dental Products, Inc. entered. Expected to close mid-November 1997. Headcount added is not explicitly disclosed. | |||
| 1997-06-28 | other | announced | 1997-08-04 | United States | Logistics / Delivery | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Teamsters Union strike against UPS commenced August 4, 1997, substantially reducing ability to fulfill shipments. Company arranged alternative delivery means at incremental cost. | ||||
| 1996-12-28 | acquisition_addition | completed | Dental, medical, veterinary and international distribution | Item_1_Business f5-10k / GLM-5.3-flash-HTML | Seventeen acquisitions during fiscal 1996: 10 dental, 3 medical, 1 veterinary supply and 3 international dental companies; 15 majority-owned (9 at 100%). Aggregate acquired net sales approximately $104.0 million; aggregate purchase price approximately $38.8 million. Employee headcount added not disclosed. | ||||||
| 1996-12-28 | acquisition_addition | completed | 1997-02-28 | Practice management software (Technology) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Pooling-of-interests acquisition of Dentrix Dental Systems completed February 28, 1997; 1996 net sales approximately $10.3 million with roughly 3,500 installed users. Headcount added not disclosed. | |||||
| 1996-12-28 | acquisition_addition | completed | United States | Dental products distribution | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Purchase transaction for the business of Smith Holden, Inc., described as the longest operating dental supply company in the US, completed after fiscal year-end 1996; Smith Holden 1996 net sales approximately $14.2 million. Headcount added not disclosed. | |||||
| 1996-12-28 | acquisition_addition | announced | 1997-03-07 | 1997-06 | United States | Medical products distribution | subsequent_events f5-10k / GLM-5.3-flash-HTML | Merger Agreement signed March 7, 1997; Micro Bio-Medics to merge into a wholly-owned subsidiary at 0.62 HSIC shares per MBMI share. MBMI fiscal 1996 net sales approximately $150.0 million and earnings approximately $1.7 million. Expected to close by mid-1997, subject to MBMI shareholder approval and Hart-Scott-Rodino clearance. Headcount not disclosed. | |||
| 1996-12-28 | acquisition_addition | completed | North America and Europe | Dental, Medical, Veterinary, International | Item_1_Business f5-10k / MiMo-V2.6-Flash-fp8-HTML | 17 acquisitions completed in FY1996 (10 dental, 3 medical, 1 veterinary, 3 international dental) with aggregate acquired net sales of ~$104.0M. No headcount figures disclosed for acquired entities. | |||||
| 1996-12-28 | acquisition_addition | announced | 1997-02-28 | 1997-02-28 | United States | Practice Management Software | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Pooling-of-interests acquisition completed 1997-02-28; Dentrix had 1996 net sales of ~$10.3M. No headcount disclosed. | |||
| 1996-12-28 | acquisition_addition | announced | United States | Dental Distribution | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Purchase transaction completed after fiscal year-end; Smith Holden had 1996 net sales of ~$14.2M. No headcount disclosed. | |||||
| 1996-12-28 | acquisition_addition | announced | 1997-03-07 | United States | Medical Distribution | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Merger agreement signed 1997-03-07; MBMI had FY1996 net sales of ~$150.0M and earnings of ~$1.7M. Exchange ratio 0.62 HSIC shares per MBMI share. No headcount disclosed. Expected completion mid-1997. |